<SEC-DOCUMENT>0001683168-24-002158.txt : 20240405
<SEC-HEADER>0001683168-24-002158.hdr.sgml : 20240405
<ACCEPTANCE-DATETIME>20240405172733
ACCESSION NUMBER:		0001683168-24-002158
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		24
FILED AS OF DATE:		20240405
DATE AS OF CHANGE:		20240405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-278188
		FILM NUMBER:		24827565

	BUSINESS ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>aethlon_s1a1.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:AEMD="http://aethlonmedical.com/20240405">
<head>
     <title>Aethlon Medical, Inc. S-1</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_AEMD_aethlonmedical.com_20240405 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20240405_20240405 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentDescription_Updating S%2D1 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0000882291 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000003" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000004" name="dei:AmendmentDescription">Updating S-1</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000005" name="dei:EntityCentralIndexKey">0000882291</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aemd-20240405.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-04-05">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-05</xbrli:startDate>
        <xbrli:endDate>2024-04-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-size: 7pt"><a href="#s1_001">Table of Contents</a></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Registration No. 333-278188</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>As filed with the Securities and Exchange Commission
on <span id="xdx_90D_edei--DocumentCreationDate_c20240405__20240405_zw4VfLN7h28d"><ix:nonNumeric contextRef="AsOf2024-04-05" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentCreationDate">April 5, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 0.75pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 16pt"><b>UNITED STATES
</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 16pt"><b>SECURITIES AND
EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 16pt; text-transform: uppercase"><b>Amendment
No. 1</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 16pt; text-transform: uppercase"><b>To</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 16pt"><b>FORM <span id="xdx_909_edei--DocumentType_c20240405__20240405_z4IQvwts0kq5"><ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000011" name="dei:DocumentType">S-1<b style="display: none">/A</b></ix:nonNumeric></span></b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 16pt"><b>REGISTRATION
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>UNDER </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>THE SECURITIES ACT OF 1933 </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 16pt"><b><span id="xdx_901_edei--EntityRegistrantName_c20240405__20240405_zt4fTAHGjKBh"><ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000012" name="dei:EntityRegistrantName">Aethlon Medical,
Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 32%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="width: 32%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="width: 32%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20240405__20240405_zzBsdDI6JTEc"><ix:nonNumeric contextRef="AsOf2024-04-05" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>3826</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20240405__20240405_zYiyvQLbRY9h"><ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000014" name="dei:EntityTaxIdentificationNumber">13-3632859</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction of</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>incorporation or organization)</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Primary Standard Industrial</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Classification Code Number)</b></p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification Number)</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20240405__20240405_zy2PrD771OJg"><ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000015" name="dei:EntityAddressAddressLine1">11555 Sorrento Valley Road</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20240405__20240405_zv7M1mPnF9l4"><ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 203</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressCityOrTown_c20240405__20240405_ztGLNZscjWM1"><ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000017" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20240405__20240405_za3Q4Yl4Lh5g"><ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000018" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric></span> <span id="xdx_905_edei--EntityAddressPostalZipCode_c20240405__20240405_zCSjHJdJAvmh"><ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000019" name="dei:EntityAddressPostalZipCode">92121</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--CityAreaCode_c20240405__20240405_zeToTGT8Tjud"><ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000020" name="dei:CityAreaCode">(619)</ix:nonNumeric></span> <span id="xdx_907_edei--LocalPhoneNumber_c20240405__20240405_zRoee0jVL6J7"><ix:nonNumeric contextRef="AsOf2024-04-05" id="Fact000021" name="dei:LocalPhoneNumber">941-0360</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address, including zip code, and telephone
number, including area code, of registrant&#8217;s principal executive offices) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>James B. Frakes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Interim Chief Executive Officer </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aethlon Medical, Inc. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>11555 Sorrento Valley Road, Suite 203</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>San Diego, CA 92121 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(619) 941-0360</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Name, address, including zip code, and telephone
number, including area code, of agent for service) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Copies to: </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 49%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="width: 49%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Julie Robinson</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Wade Andrews</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Cooley LLP</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>10265 Science Center Drive</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>San Diego, CA 92121</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(858) 550-6000</b></p></td>
    <td style="vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>M. Ali Panjwani</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pryor Cashman LLP</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>7 Times Square</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>New York, NY 10036-6569</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Telephone: (212) 326-0846</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fax: (212) 326-0806</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Approximate date of commencement of proposed sale to the public</b>:
As soon as practicable after the effective date of this registration statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If any of the securities being registered on this Form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering.&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration
statement for the same offering.&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration
statement for the same offering.&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging
growth company&#8221; in Rule 12b-2 of the Exchange Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt">Large&#160;accelerated&#160;filer</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Accelerated&#160;filer</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20240405__20240405_znXYARXfotBe"><ix:nonNumeric contextRef="AsOf2024-04-05" format="ixt-sec:entityfilercategoryen" id="Fact000022" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Smaller&#160;reporting&#160;company</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--EntitySmallBusiness_c20240405__20240405_z3PtadmD7HSf"><ix:nonNumeric contextRef="AsOf2024-04-05" format="ixt:booleantrue" id="Fact000023" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td>&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Emerging&#160;growth&#160;company</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20240405__20240405_z9jXQwnZEmBj"><ix:nonNumeric contextRef="AsOf2024-04-05" format="ixt:booleanfalse" id="Fact000024" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Registrant hereby amends this registration statement on such
date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states
that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933,
as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting
pursuant to said Section&#160;8(a), may determine. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 0.75pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="color: Red"><b>The information in this prospectus is
not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities
in any state where the offer or sale is not permitted. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="color: Red">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="color: Red"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><b>SUBJECT TO COMPLETION, DATED APRIL
5, 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><img src="image_001.jpg" alt=""/></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Up to 4,651,162
Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Pre-Funded Warrants
to Purchase up to 4,651,162 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Warrants to Purchase
up to 4,651,162 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Placement Agent
Warrants to Purchase up to 186,046 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Shares of Common
Stock Issuable upon the Exercise of the Warrants,</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>Pre-Funded Warrants
and Placement Agent Warrants</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are offering in a best-efforts offering up to 4,651,162 shares
of common stock, par value $0.001 per share (&#8220;common stock&#8221;), and accompanying warrants to purchase up to 4,651,162 shares
of our common stock at a combined public offering price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per
share of common stock and accompanying warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are also offering to those purchasers, if any, whose purchase of
our common stock in this offering would otherwise result in such purchaser, together with its affiliates and certain related parties,
beneficially owning more than 4.99% of our outstanding common stock immediately following the consummation of this offering, the opportunity,
in lieu of purchasing common stock, to purchase pre-funded warrants to purchase shares of our common stock, or pre-funded warrants. Each
pre-funded warrant will be exercisable for one share of our common stock (subject to adjustment as provided for therein) at any time at
the option of the holder until such pre-funded warrant is exercised in full, provided that the holder will be prohibited from exercising
pre-funded warrants for shares of our common stock if, as a result of such exercise, the holder, together with its affiliates and certain
related parties, would own more than 4.99% of the total number of shares of our common stock then issued and outstanding. However, any
holder may increase such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall
not be effective until 61 days after notice to us. The purchase price of each pre-funded warrant will equal the price per share at which
shares of our common stock and accompanying warrants to purchase common stock are being sold to the public in this offering, minus $0.001,
and the exercise price of each pre-funded warrant will equal $0.001 per share of common stock. For each pre-funded warrant purchased in
this offering in lieu of common stock, we will reduce the number of shares of common stock we are offering by one. Pursuant to this prospectus,
we are also offering the shares of common stock issuable upon the exercise of the warrants, pre-funded warrants and placement agent warrants
offered hereby.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each share of our common stock, or pre-funded warrant in lieu thereof,
is being sold together with a warrant to purchase one share of our common stock. Each warrant will have an exercise price per of $ per
share (representing 100% of the combined public offering price per share of common stock (or pre-funded warrant) and accompanying warrant
in this offering), will be immediately exercisable and will expire on the fifth anniversary of the original issuance date. The shares
of our common stock and warrants are immediately separable and will be issued separately, but will be purchased together in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This offering will terminate on
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
, 2024, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have
one closing for all the securities purchased in this offering. The combined public offering price per share (or pre-funded warrant)
and warrant will be fixed for the duration of this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have engaged Maxim Group LLC, or the placement agent, to act as
our exclusive placement agent in connection with the securities offered by this prospectus. The placement agent has agreed to use its
reasonable best efforts to arrange for the sale of the securities offered by this prospectus. The placement agent is not purchasing or
selling any of the securities we are offering, and the placement agent is not required to arrange the purchase or sale of any specific
number of securities or dollar amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on The Nasdaq Capital Market under the
symbol &#8220;AEMD.&#8221; On April 3, 2024, the last reported sale price of our common stock on The Nasdaq Capital Market
was $1.72 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The public offering price for the securities offered by this prospectus
will be determined between us and the investors in this offering at the time of pricing, and may be at a discount to the current market
price. Therefore, the recent market price of $1.72 per share of common stock used throughout this prospectus may not be indicative
of the actual combined public offering price for our common stock or pre-funded warrants, as applicable, and the accompanying warrant.
There is no established trading market for the warrants or pre-funded warrants and we do not expect a market to develop. In addition,
we do not intend to apply for the listing of the warrants or pre-funded warrants on any national securities exchange or other trading
market. Without an active trading market, the liquidity of the warrants and the pre-funded warrants will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have agreed to pay the placement agent the placement agent fees
set forth in the table below, which assumes that we sell all of the securities offered by this prospectus. See &#8220;<a href="#s1_010">Plan of Distribution</a>&#8221;
on page 16 of this prospectus for more information regarding these arrangements. There is no minimum number of shares of common
stock or pre-funded warrants or minimum aggregate amount of proceeds that is a condition for this offering to close. We may sell fewer
than all of the shares of common stock and pre-funded warrants (and accompanying warrants) offered hereby, which may significantly reduce
the amount of proceeds received by us, and investors in this offering will not receive a refund if we do not sell all of the securities
offered hereby. In addition, we have not established an escrow account in connection with this offering. Because there is no escrow account
and no minimum number of securities or amount of proceeds, investors could be in a position where they have invested in us, but we have
not raised sufficient proceeds in this offering to adequately fund the intended uses of the proceeds as described in this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Per Share and Accompanying Warrant</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Per Pre-Funded Warrant and Accompanying Warrant</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 55%">Public offering price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"/><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Placement Agent fees<sup>(1)</sup></span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="border-bottom: Black 1pt solid; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-size: 10pt">Proceeds, before expenses, to us<sup>(2)</sup></span></td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"/><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"/><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"/><td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td></tr>
  </table>



<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-size: 10pt">(1)</span></td>
    <td style="width: 97%"><span style="font-size: 10pt">We have agreed to (i)&#160;pay the placement agent a cash fee equal to 6.5% of the aggregate gross proceeds raised at the closing of this offering, and (ii)&#160;issue warrants to the placement agent exercisable for a number of shares of common stock equal to 4% of the total number of shares of common stock issued in this offering. We have also agreed to reimburse the placement agent for certain expenses and closing costs. See &#8220;Plan of Distribution&#8221; for additional information and a description of the compensation payable to the placement agent. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-size: 10pt">(2)</span></td>
    <td style="width: 97%"><span style="font-size: 10pt">Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above. For more information, see &#8220;Plan of Distribution.&#8221; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a &#8220;smaller reporting company&#8221; as defined under the
federal securities laws and, under applicable Securities and Exchange Commission rules, we have elected to comply with certain reduced
public company reporting and disclosure requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus, including such information that is incorporated by
reference, contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All the summaries are qualified in their entirety by the actual documents. Copies of some of
the documents referred to herein have been filed or have been incorporated by reference as exhibits to the registration statement of which
this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the heading &#8220;Where
You Can Find Additional Information.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Investing in our securities involves a high degree of risk.
Please read &#8220;<a href="#s1_004">Risk Factors</a>&#8221; beginning on page 6 of this prospectus as well as any other risk
factors and other information contained in any other document that is incorporated by reference herein.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation
to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delivery of the common stock, pre-funded warrants and accompanying
warrants offered hereby is expected to be made on or about April&#160;&#160;&#160;&#160;&#160;, 2024, subject to satisfaction
of certain customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt; background-color: white"><b>Maxim
Group LLC</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>The date of this prospectus is April&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2024. </b></p>




<hr style="height: 3px; width: 100%"/>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 2; Name: PageNo -->ii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s1_001"></span><b>TABLE OF CONTENTS<span style="font-family: Times New Roman, Times, Serif"><sup></sup></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_002">Summary</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">1</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_004">Risk Factors</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">6</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_005">Special Note Regarding Forward-Looking Statements</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">9</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_006">Use of Proceeds</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">10</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_008">Description of Capital Stock</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">11</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_009">Description of the Securities We Are Offering</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">13</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_010">Plan of Distribution</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">16</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_011">Legal Matters</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_012">Experts</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_013">Market and Industry Data</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_014">Where You Can Find Additional Information</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">22</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt"><span style="font-size: 10pt"><a href="#s1_015">Incorporation of Certain Information by Reference</a></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">23</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not, and the placement agent has not, authorized anyone to
provide you with information that is different from that contained in this prospectus or in any free writing prospectus we may authorize
to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. Neither the delivery of this prospectus nor the sale of our securities means that the information
contained in this prospectus or any free writing prospectus is correct after the date of this prospectus or such free writing prospectus.
This prospectus is not an offer to sell or the solicitation of an offer to buy our securities in any circumstances under which the offer
or solicitation is unlawful. The information contained in this prospectus is current only as of the date of this prospectus, regardless
of the time of delivery of this prospectus or of any sale of our common stock or warrants. Our business, financial condition, results
of operations and prospects may have changed since that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For investors outside the United States: We have not, and the placement
agent has not, taken any action that would permit this offering or possession or distribution of this prospectus in any jurisdiction where
action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this
prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities covered hereby and the
distribution of this prospectus outside the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise indicated, information contained in this prospectus
concerning our industry and the markets in which we operate, including our general expectations and market position, and market opportunity,
is based on information from our own management estimates and research, as well as from industry and general publications and research,
surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of
our industry and assumptions based on such information and knowledge, which we believe to be reasonable. Our management estimates have
not been verified by any independent source, and we have not independently verified any third-party information. In addition, assumptions
and estimates of our and our industry&#8217;s future performance are necessarily subject to a high degree of uncertainty and risk due
to a variety of factors, including those described in &#8220;<a href="#s1_004">Risk Factors.</a>&#8221; These and other factors could cause our future performance
to differ materially from our assumptions and estimates. See &#8220;<a href="#s1_005">Special Note Regarding Forward-Looking Statements.</a>&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We further note that the representations, warranties and covenants
made by us in any agreement that is filed as an exhibit to the registration statement of which this prospectus is a part were made solely
for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such
agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or
covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied
on as accurately representing the current state of our affairs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus contains references to our trademarks, including <span style="background-color: white">Aethlon
Medical, Inc.</span> and Hemopurifier, and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names
referred to in this prospectus, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such
references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or
the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#8217;
trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 3; Name: PageNo -->iii<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s1_002"></span>SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><i>This summary highlights information contained in other parts of
this prospectus or incorporated by reference into this prospectus from our filings with the Securities and Exchange Commission, or SEC,
listed in the section of the prospectus entitled &#8220;Incorporation of Certain Information by Reference.&#8221; Because it is only a
summary, it does not contain all of the information that you should consider before purchasing our securities in this offering and it
is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere or incorporated
by reference into this prospectus. You should read the entire prospectus, the registration statement of which this prospectus is a part,
and the information incorporated by reference herein in their entirety, including the &#8220;<a href="#s1_004">Risk Factors</a>&#8221; and our financial statements
and the related notes incorporated by reference into this prospectus, before purchasing our securities in this offering. Unless the context
requires otherwise, references in this prospectus to &#8220;Aethlon,&#8221; the &#8220;Company&#8221;, &#8220;we,&#8221; &#8220;us&#8221;
and &#8220;our&#8221; refer to Aethlon Medical, Inc.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We are a medical therapeutic
company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening
viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening
viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes and exosomal particles from biological
fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote
immune suppression and metastasis, and in life-threatening infectious diseases. The <span>U.S. Food and
Drug Administration, or </span>FDA, has designated the Hemopurifier as a &#8220;Breakthrough Device&#8221; for two independent indications:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy,
and with cancer types in which exosomes or exosomal particles have been shown to participate in the development or severity of the disease;
and</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>the treatment of life-threatening viruses that are not addressed with approved therapies.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe the Hemopurifier can be a substantial
advancement in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove harmful exosomes
or exosomal particles that promote the growth and spread of tumors through multiple mechanisms. We are currently working with our contract
research organization, or CRO, on preparations to conduct a planned clinical trial in Australia in patients with solid tumors, including
head and neck cancer, gastrointestinal cancers and other cancers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In January 2023, we entered into an agreement
with North American Science Associates, LLC, or NAMSA, a world leading medical technology CRO offering global end-to-end development services,
to oversee our planned clinical trials investigating the Hemopurifier for oncology indications. Pursuant to the agreement, NAMSA agreed
to manage our planned clinical trials of the Hemopurifier for patients in the United States and Australia with various types of cancer
tumors. We anticipate that the initial clinical trials will begin in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also believe the Hemopurifier can be part
of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an
already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used in the past to treat individuals
infected with human immunodeficiency virus, or HIV, hepatitis-C and Ebola.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally,&#160;<i>in vitro,</i>&#160;the
Hemopurifier has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus,
Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, Monkeypox virus
and the reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government
or non-government research institutes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 17, 2020, the FDA approved a supplement to our open Investigational
Device Exemption, or IDE, for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients with SARS-CoV-2/COVID-19,
or COVID-19, in a new feasibility study.&#160;<span>That study was designed to enroll up to 40 subjects
at up to 20 centers in the United States. Subjects were to have established laboratory diagnosis of COVID-19, be admitted to an intensive
care unit, or ICU, and have acute lung injury and/or severe or life-threatening disease, among other criteria. Endpoints for this study,
in addition to safety, included reduction in circulating virus, as well as clinical outcomes (NCT # 04595903).&#160;</span>In June 2022,
the first patient in this study was enrolled and completed the Hemopurifier treatment phase of the protocol. Due to the lack of COVID-19
patients in the ICUs of our trial sites, we terminated this study in 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under Single Patient Emergency Use regulations,
Aethlon has treated two patients with COVID-19 with the Hemopurifier, in addition to the COVID-19 patient treated with our Hemopurifier
in our COVID-19 clinical trial discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We previously reported a disruption in our
Hemopurifier supply, as our then existing supply of Hemopurifiers expired on September 30, 2022 and, also as previously disclosed, we
are dependent on FDA approval of qualified suppliers to manufacture our Hemopurifier. Our intended transition to a new supplier for galanthus
nivalis agglutinin, or GNA, a component of our Hemopurifier, continues to be delayed as we work with the FDA for approval of our supplement
to our IDE, which is required to make this manufacturing supplier change. We are working with the FDA to qualify this second supplier
of our GNA. We also are in the process of completing final testing in order to begin manufacturing Hemopurifiers at our new manufacturing
facility in San Diego for use in planned U.S. clinical trials, using GNA from our current supplier. The first manufacturing lot that incorporates
the GNA from our original supplier was approved and released at the end of December 2023. We also have sufficient Hemopurifiers on hand
for use in our planned Australia and India oncology trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2022, we launched a wholly owned
subsidiary in Australia, formed to conduct clinical research, seek regulatory approval and commercialize our Hemopurifier in that country.
The subsidiary will initially focus on the planned oncology trials in Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also obtained ethics review board, or ERB, approval from and entered
into a clinical trial agreement with Medanta Medicity Hospital, a multi-specialty hospital in Delhi NCR, India, for a COVID-19 clinical
trial at that location. We now have two sites in India for this trial with the Medanta Medicity Hospital and Maulana Azad Medical College,
or MAMC. One patient has been treated to date, however, we have been informed by our contract research organization that a new COVID-19
subvariant was detected in India recently. Our COVID-19 trial in India remains open in the event that there are COVID-19 admissions to
the intensive care units at our sites in India.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The relevant authorities in India have accepted
the use of our Hemopurifiers made with the GNA from our new supplier.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2023, we received ERB approval from
the MAMC, for a second site for our clinical trial in India to treat severe COVID-19. MAMC was established in 1958 and is located in New
Delhi, India. MAMC is affiliated with the University of Delhi and is operated by the Delhi government.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In October 2023, we&#160;<span>announced
that we received clearance from the Drug Controller General of India, the central drug authority in India, to conduct a Phase 1 safety,
feasibility and dose-finding trial of our Hemopurifier&#160;in patients with solid tumors who have stable or progressive disease during
anti-PD-1 monotherapy treatment, such as Keytruda<sup>&#174;</sup>&#160;or Opdivo<sup>&#174;</sup>. The trial is expected to begin following
completion of an internal in vitro binding studies of relevant targets, and subsequent approval by the respective Ethics Boards of interested
sites in India.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span>&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Additionally, we announced that we have begun
investigating the use of our Hemopurifier in the organ transplant setting. Our objective is to confirm that the Hemopurifier, in our translational
studies, when incorporated into a machine perfusion organ preservation circuit, can remove harmful viruses and exosomes or exosomal particles
from recovered organs. We initially are focused on recovered kidneys, in a research collaboration with 34 Lives, PBC. We have previously
demonstrated the removal of multiple viruses and exosomes from buffer solutions, <i>in vitro</i>, utilizing a scaled-down version of our
Hemopurifier. This process potentially may reduce complications following transplantation of the recovered organ, which can include viral
infection, delayed graft function and rejection. We believe this new approach could be additive to existing technologies that currently
are in place to increase the number of viable kidneys for transplant.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Successful outcomes of human trials will also
be required by the regulatory agencies of certain foreign countries where we plan to market and sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In addition to the foregoing, we are monitoring
closely the impact of inflation, recent bank failures and the war between Russia and Ukraine and the military conflicts in Israel and
the surrounding areas, as well as related political and economic responses and counter-responses by various global factors on our business.
Given the level of uncertainty regarding the duration and impact of these events on capital markets and the U.S. economy, we are unable
to assess the impact on our timelines and future access to capital. The full extent to which inflation, recent bank failures and the ongoing
military conflicts will impact our business, results of operations, financial condition, clinical trials and preclinical research will
depend on future developments, as well as the economic impact on national and international markets that are highly uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Recent Developments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On October 4, 2023, the Company completed a reverse split of its outstanding shares of common stock at a ratio of 1-for-10.
In connection with the reverse stock split, every 10 shares of the Company&#8217;s issued and outstanding common stock was automatically
converted into one share of the Company&#8217;s common stock. Any fractional shares resulting from the reverse split were rounded up to
the next whole share. All common stock amounts and prices in this registration statement reflect the consummation of the reverse split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Implications of Being A Smaller Reporting
Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent that we continue to qualify as a &#8220;smaller reporting
company,&#8221; as such term is defined in Rule 12b-2 under the Exchange Act, we will continue to be permitted to make certain reduced
disclosures in our periodic reports and other documents that we file with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On March 10, 1999, Aethlon, Inc., a California
corporation, Hemex, Inc., a Delaware corporation and the accounting predecessor to Aethlon, Inc., and Bishop Equities, Inc., a publicly
traded Nevada corporation, completed an Agreement and Plan of Reorganization structured to result in Bishop Equities, Inc.'s acquisition
of all of the outstanding common stock of Aethlon, Inc. and Hemex, Inc. Under the plan's terms, Bishop Equities, Inc. issued shares of
its common stock to the stockholders of Aethlon, Inc. and Hemex, Inc. such that Bishop Equities, Inc. then owned 100% of each company.
Upon completion of the transaction, Bishop Equities, Inc. was renamed Aethlon Medical, Inc. Our executive offices are located at 11555
Sorrento Valley Road, Suite 203, San Diego, California 92121. Our telephone number is (619) 941-0360. Our website address is www.aethlonmedical.com.
The information contained on, or that can be accessed through, our website is not part of, and is not incorporated into, this prospectus,
and you should not rely on any such information in making the decision of whether to purchase shares of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s1_003"></span>THE OFFERING </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 34%; text-align: justify"><span style="font-size: 10pt">Issuer</span></td>
    <td style="width: 66%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon Medical, Inc.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Common stock offered by us</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4,651,162 shares</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Pre-funded warrants</span></td>
    <td style="text-align: justify"><p style="margin-top: 0; margin-bottom: 0">We are also offering to those purchasers, if any, whose
                                    purchase of common stock in this offering would otherwise result in such purchaser, together with
                                    its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding
                                    common stock immediately following the consummation of this offering, the opportunity, in lieu of
                                    purchasing common stock, to purchase&#160;pre-funded&#160;warrants to purchase up to 4,651,162
                                    shares of our common stock. For each&#160;pre-funded&#160;warrant we sell, the number of shares
                                    of common stock we are offering will be decreased on a&#160;one-for-one&#160;basis. The purchase
                                    price of each&#160;pre-funded&#160;warrant will equal the price per share at which the shares of
                                    common stock and accompanying warrants to purchase common stock are being sold to the public in this
                                    offering, minus $0.001, and the exercise price of each pre-funded warrant will be $0.001
                                    per share of common stock.</p>
                                    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                    <p style="margin-top: 0; margin-bottom: 0">Each pre-funded warrant will be exercisable immediately upon issuance and will
                                    not expire. This prospectus also relates to the offering of the shares of common stock issuable upon exercise of
                                    such&#160;pre-funded&#160;warrants. See &#8220;<a href="#s1_009">Description of the Securities We
                                    are&#160;Offering</a>&#8212;Pre-Funded&#160;Warrants&#8221; for a discussion on the terms of the&#160;pre-funded&#160;warrants.
                                    &#160; Each&#160;pre-funded&#160;warrant is exercisable for one share of our common stock (subject to adjustment as provided
                                    therein) at any time at the option of the holder, provided that the holder will be prohibited from exercising its&#160;pre-funded
                                    warrant for shares of our common stock if, as a result of such exercise, the holder, together with its affiliates and certain
                                    related parties, would own more than 4.99% of the total number of shares of our common stock then issued and outstanding. However,
                                    any holder may increase such percentage to any other percentage not in excess of 9.99%, provided that any increase in such
                                    percentage shall not be effective until 61 days after notice to us.</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Warrants</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrants to purchase up to 4,651,162
    shares of our common stock. Each share of our common stock, or pre-funded warrant in lieu thereof, is being sold together with a
    warrant to purchase one share of our common stock. Each warrant will have an initial exercise price of $ per share (representing
    100% of the combined public offering price per share of common stock (or pre-funded warrant) and accompanying warrant in this offering),
    subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications,
    reorganizations or similar events affecting our common stock. The warrants will be immediately exercisable and will expire on the
    fifth anniversary of the original issuance date. This prospectus also relates to the offering of the shares of common stock issuable
    upon exercise of such warrants.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To better understand the terms of the warrants,
    you should carefully read the &#8220;Description of Securities We are Offering &#8211; Warrants&#8221;. You should also read the form
    of warrant, which is filed as an exhibit to the registration statement that includes this prospectus.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Placement agent warrants</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We have agreed to issue to the placement agent warrants to purchase a number of shares of common stock equal to 4% of the total number of shares of common stock issued in this offering. The placement agent&#8217;s warrant will be &#160;non-exercisable for six (6) months after the date of the closing and will expire five years after the commencement of sales of the offering. The placement agent&#8217;s warrant will be exercisable for the purchase of shares of our common stock at a price per share equal to the combined purchase price per share of common stock (or pre-funded warrant) and accompanying warrant in this offering. We are also registering the shares of common stock issuable upon the exercise of the placement agent&#8217;s warrants.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

</div>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<div style="border: Black 1pt solid; margin: 0.1in; padding: 0.1in">

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 34%"><span style="font-size: 10pt">Shares of common stock outstanding after <br/>
the offering</span></td>
    <td style="width: 66%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">7,247,700 shares
    (assuming <span style="background-color: white">no sale of any&#160;pre-funded&#160;warrants and assuming none of the warrants to
    purchase common stock issued in this offering </span>or the placement agent&#8217;s warrant issued in this offering are exercised).</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Use of proceeds</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently expect to use the net proceeds from
    this offering for general corporate purposes, which may include research and development expenses, clinical trial expenses, capital expenditures
    and working capital. For additional information please refer to the section entitled &#8220;Use of Proceeds&#8221; of this prospectus.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Market symbol and trading</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on The Nasdaq Capital
    Market under the symbol &#8220;AEMD.&#8221; There is no established trading market for the warrants or pre-funded warrants and we do not
    expect a market to develop. In addition, we do not intend to apply for the listing of the warrants or the pre-funded warrants on any national
    securities exchange or other trading market. Without an active trading market, the liquidity of the warrants and the pre-funded warrants
    will be limited.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">Risk factors</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Investing in our securities involves a high degree of risk. You should carefully review and consider the &#8220;<a href="#s1_004">Risk Factors</a>&#8221; section of this prospectus for a discussion of factors to consider before deciding to purchase any of our securities in this offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of shares of our common stock to be outstanding after this
offering is based on 2,596,538 shares of our common stock outstanding as of December&#160;31, 2023 and excludes as of such date:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>142,898 shares of common stock issuable upon the exercise of outstanding stock options under our equity incentive plan at a weighted-average
exercise price of $22.34 per share;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>18,492 shares of common stock issuable pursuant to outstanding restricted stock units;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>140,238 shares of common stock reserved for future issuance under our equity incentive plan; and</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">32,676 shares of common stock reserved for issuance upon the exercise of outstanding warrants at a weighted-average
exercise price of $20.09 per share.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Unless otherwise indicated, all information in
this prospectus assumes no exercise of the outstanding options or warrants described above; no issuance of any shares of common stock
issuable upon the settlement of outstanding restricted stock units described above; no sale of any pre-funded warrants in lieu of common
stock in this offering; and no exercise of the placement agent&#8217;s warrant or the warrants to be issued to the purchasers of common
stock or pre-funded warrants in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: center"><span id="s1_004"></span><b>RISK FACTORS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Investing in our securities involves a high degree of risk. You
should consider carefully the risks described below, together with all of the other information included or incorporated by reference
in this prospectus, including the risks and uncertainties discussed under &#8220;<a href="#s1_004">Risk Factors</a>&#8221; in our Annual Report on Form 10-K
for the year ended March&#160;31, 2023, which has been filed with the SEC and is incorporated by reference in this prospectus, as well
as any updates thereto contained in subsequent filings with the SEC or any free writing prospectus, before deciding whether to purchase
our securities in this offering. All of these risk factors are incorporated herein in their entirety. The risks described below and incorporated
by reference are material risks currently known, expected or reasonably foreseeable by us. However, the risks described below are not
the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business,
operating results, prospects or financial condition. If any of these risks actually materialize, our business, prospects, financial condition,
and results of operations could be seriously harmed. This could cause the trading price of our common stock and the value of the warrants
to decline, resulting in a loss of all or part of your investment.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Relating to This Offering</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>This is a best-efforts offering, no minimum amount of securities
is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term
business plans.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The placement agent has agreed to use its reasonable best efforts to
solicit offers to purchase the securities in this offering. The placement agent has no obligation to buy any of the securities from us
or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum number
of securities that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as
a condition to the closing of this offering, the actual offering amount, placement agent fees and proceeds to us are not presently determinable
and may be substantially less than the maximum amounts set forth herein. We may sell fewer than all of the securities offered hereby,
which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the
event that we do not sell an amount of securities sufficient to support our continued operations, including our near-term continued operations.
Thus, we may not raise the amount of capital we believe is required for our operations in the short-term and may need to raise additional
funds to complete such short-term operations. Such additional fundraises may not be available or available on terms acceptable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>You may experience dilution as a result of purchasing</i></b><b><i>
our securities in this offering.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent the offering price per share exceeds our net tangible
book value per share of common stock, purchasers in this offering will suffer immediate dilution in their investment. As of December 31,
2023, our net tangible book value per share was $2.56 per share. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We have broad discretion in the use of the net proceeds we receive
from this offering and may not use them effectively.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our management will have broad discretion in the application of the
net proceeds we receive in this offering, including for any of the purposes described in the section entitled &#8220;Use of Proceeds,&#8221;
and you will not have the opportunity as part of your investment decision to assess whether our management is using the net proceeds appropriately.
Because of the number and variability of factors that will determine our use of our net proceeds from this offering, their ultimate use
may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could result
in financial losses that could have a material adverse effect on our business and cause the price of our common stock to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Future sales of substantial amounts of our common stock could
adversely affect the market price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may choose to raise additional capital due to market conditions
or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If additional capital
is raised through the sale of equity or convertible debt securities, or perceptions that those sales could occur, the issuance of these
securities could result in further dilution to investors purchasing our common stock in this offering or result in downward pressure on
the price of our common stock, and our ability to raise capital in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Holders of our warrants and pre-funded warrants will have no
rights as a common stockholder until they acquire our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Until you acquire shares of our common stock upon exercise of your
warrants or pre-funded warrants, you will have no rights with respect to shares of our common stock issuable upon exercise of your warrants
or pre-funded warrants. Upon exercise of your warrants or pre-funded warrants, you will be entitled to exercise the rights of a common
stockholder only as to matters for which the record date occurs after the exercise date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The warrants may not have any value.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each warrant will have an exercise price of not less than 100% of
the last reported sale price of our common stock as of the close of the trading day immediately preceding the pricing of this offering
and will expire on the fifth anniversary of the date they first become exercisable. In the event our common stock price does not
exceed the exercise price of the warrants during the period when the warrants are exercisable, the warrants may not have any value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>There is no public market for the warrants to purchase shares
of our common stock or pre-funded warrants being offered in this offering.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There is no established public trading market for the warrants or pre-funded
warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the
warrants or pre-funded warrants on any national securities exchange or other nationally recognized trading system, including The Nasdaq
Capital Market. Without an active trading market, the liquidity of the warrants and pre-funded warrants will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>There is substantial doubt about our ability to continue as a
going concern We will need to raise additional capital to fund our operations in the future. If we are unsuccessful in attracting new
capital, we may not be able to continue operations or may be forced to sell assets to do so. Alternatively, capital may not be available
to us on favorable terms, or if at all. If available, financing terms may lead to significant dilution of our stockholders&#8217; equity.
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">We have never been profitable.
We generated revenues during the fiscal years ended March 31, 2023 and 2022 in the amounts of $574,245 and $294,165, respectively, primarily
from our contract with the National Institutes of Health, which ended in September 2022. It is possible that we may not be able to enter
into future government contracts. Future profitability, if any, will require the successful commercialization of our Hemopurifier technology
or any other product that we develop or from additional government contract or grant income we may obtain. We may not be able to successfully
commercialize the Hemopurifier or any other products, and even if commercialization is successful, we may never be profitable. </span>Based
on our existing resources prior to this offering, we expect that our resources will only be sufficient to fund our planned operations
and expenditures through December 2024. If we were to receive net proceeds of $7.00 million from this offering, we believe that
the net proceeds from this offering, together with our existing cash, cash equivalents and short-term investments as of December 31,
2023, would be sufficient to fund our planned operations through&#160;September&#160;2025. In addition, potentially changing circumstances,
including those related to inflation, recent bank failures and ongoing military conflicts may also result in the depletion of our capital
resources more rapidly than we currently anticipate. These circumstances raise substantial doubt about our ability to continue as a going
concern. We will need to obtain additional funds to finance our operations. Additional capital may not be available at such times or
amounts as needed by us. Historically we have financed our business in part by access to the capital markets. However, the current volatility
in the equity markets, coupled with the trading price of our common stock create additional challenges to raising a sufficient amount
of capital through an equity financing in the near term. Even if capital is available, it might be available only on unfavorable terms.
Any additional equity or convertible debt financing into which we enter could be dilutive to our existing stockholders and investors
in this offering. Any future debt financing into which we enter may impose covenants upon us that restrict our operations, including
limitations on our ability to incur liens or additional debt, pay dividends, repurchase our stock, make certain investments and engage
in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms
that are not favorable to us or our stockholders. If we raise additional funds through collaboration and licensing arrangements with
third parties, we may need to relinquish rights to our technologies or our products or grant licenses on terms that are not favorable
to us. If access to sufficient capital is not available as and when needed, our business will be materially impaired, and we may be required
to cease operations, curtail one or more product development programs, or significantly reduce expenses, sell assets, seek a merger or
joint venture partner, file for protection from creditors or liquidate all of our assets. Any of these factors could harm our operating
results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s1_005"></span>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus and the documents incorporated herein by reference
contain forward-looking statements. The forward-looking statements are contained principally in the sections entitled &#8220;Summary,&#8221;
&#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;
and &#8220;Business&#8221; in this prospectus or the documents incorporated herein by reference. These statements relate to future events
or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied
by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to successfully commercialize our products and technology, including our Hemopurifier;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to raise additional capital to meet our working capital needs;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>the timing and results of future clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to successfully complete our clinical trials;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to identify and work with large-scale contracts with medical device manufacturers;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to manufacture the Hemopurifier;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>the impact of inflation, recent bank failures and military conflicts, as well as related political and economic responses on our business;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to attract and retain executive management and directors;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>the regulatory landscape for our products, domestically and internationally and our ability to comply with changing government regulations;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to comply with the listing requirements of the Nasdaq Capital Market and maintain our listing on the Nasdaq Capital Market;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our expectations regarding growth potential for our business in the organ transplant setting;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to secure regulatory clearance or approval, domestically and internationally, for the clinical use of our products;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>any estimates regarding expenses, future revenue and capital requirements;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to protect our proprietary technology through patent protection;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our product liability exposure;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to sustain and manage growth, including our ability to develop new products and enter new markets;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our ability to achieve sufficient market acceptance of any of our products or product candidates; and</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our expected net proceeds from this offering and the use of the net proceeds from this offering.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In some cases, you can identify these statements by terms such as &#8220;anticipate,&#8221;
&#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221;
&#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;continue,&#8221; &#8220;seek,&#8221; &#8220;project,&#8221; &#8220;should,&#8221;
&#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions. You should be aware that the occurrence
of any of the events discussed under the heading &#8220;Risk Factors&#8221; in this prospectus and any documents incorporated by reference
herein could substantially harm our business, operating results and financial condition and that if any of these events occurs, it could
adversely affect the value of an investment in our common stock. In addition, statements that &#8220;we believe&#8221; and similar statements
reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the
statement is made, and while we believe such information forms a reasonable basis for such statements, such information may be limited
or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all
potentially available relevant information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You should carefully read this prospectus, the documents that we incorporate
by reference into this prospectus and the documents we reference in this prospectus and have filed as exhibits to the registration statement,
of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from
what we expect. We qualify all of the forward-looking statements in this prospectus by these cautionary statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking
statements, whether as a result of new information, future events or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus also refers to estimates and other statistical data
made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number
of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions
and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high
degree of uncertainty and risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s1_006"></span><b>USE OF PROCEEDS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We estimate that the net proceeds of this offering will be approximately
$7.00 million, based on the assumed combined public offering price of $1.72 per share and accompanying warrant
(the last reported sale price of our common stock on The Nasdaq Capital Market on April 3, 2024), after deducting the placement
agent fees and estimated offering expenses payable by us, and excluding the proceeds, if any, from the exercise of the warrants. Each
$0.10 increase (decrease) in the assumed combined public offering price of $1.72 per share and accompanying warrant would increase
(decrease) the net proceeds to us from this offering by approximately $0.43 million, assuming the number of shares and warrants
offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the placement agent fees and estimated
offering expenses payable by us. We may also increase or decrease the number of shares of our common stock and warrants we are offering.
Each 1.0&#160;million share increase (decrease) in the number of shares sold in this offering would increase (decrease) the expected
net proceeds of the offering to us by approximately $1.61 million, assuming that the assumed combined public offering price
per share and accompanying warrant remains the same.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We currently intend to use the net proceeds of the offering for general
corporate purposes, which will include research and development expenses, clinical trial expenses, capital expenditures and working capital.
We may also use a portion of the net proceeds from this offering to in-license, acquire, or invest in complementary businesses, technologies,
products or assets. However, we have no current plans, commitments or obligations to do so. P<span style="background-color: white">ending
use of the net proceeds, we intend to invest the proceeds in a variety of capital preservation instruments, including short-term, investment-grade,
interest-bearing instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We cannot currently allocate specific percentages of the net proceeds
to us from this offering that we may use for the purposes specified above and our management will have broad discretion in the allocation
of the net proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s1_008"></span>DESCRIPTION OF CAPITAL STOCK </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description of our capital stock is intended as a summary
only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified in its entirety
by reference to, our articles of incorporation, our bylaws and applicable provisions of Nevada corporate law. You should read our articles
of incorporation and bylaws, which have been publicly filed with the SEC, for the provisions that are important to you.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Authorized Capital Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our authorized capital consists of 60,000,000 shares of common stock,
par value $0.001 per share. As of April 5, 2024, there were <span style="background-color: white">2,629,275</span> shares
of common stock issued and outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The holders of our common stock are entitled to one vote per share
on all matters to be voted on by the stockholders. Holders of common stock are entitled to receive ratably such dividends as may be declared
by the Board of Directors out of funds legally available therefor. If we liquidate, dissolve or wind up, holders of common stock are entitled
to share ratably in all assets remaining after payment of all debts and other liabilities. Holders of common stock have no preemptive,
conversion or subscription rights. There are no redemption or sinking fund provisions applicable to the common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our bylaws provide that stockholders representing a majority of the
voting power of our capital stock, represented in person or by proxy (regardless of whether the proxy has authority to vote on all matters),
are necessary to constitute a quorum for the transaction of business at any meeting, but at any time during which shares of our capital
stock are listed for trading on Nasdaq, stockholders representing not less than 33 1/3% of the voting power of our capital stock, represented
in person or by proxy (regardless of whether the proxy has authority to vote on all matters), are necessary to constitute a quorum for
the transaction of business at any meeting of stockholders. Except as otherwise required or permitted by Nevada law or our articles of
incorporation or bylaws, action by the stockholders entitled to vote on a matter, other than the election of directors, is approved by
and is the act of the stockholders if the number of votes cast in favor of the action exceeds the number of votes cast in opposition to
the action. If a quorum is present, directors are elected by a plurality of the votes cast.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anti-Takeover Effects of Certain Provisions of Nevada Law and Our
Articles of Incorporation and Bylaws</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nevada&#8217;s &#8220;combinations with interested stockholders&#8221;
statutes, NRS 78.411 through 78.444, inclusive, prohibit specified types of business &#8220;combinations&#8221; between certain Nevada
corporations and any person deemed to be an &#8220;interested stockholder&#8221; for two years after such person first becomes an &#8220;interested
stockholder&#8221; unless the corporation&#8217;s board of directors approves the combination (or the transaction by which such person
becomes an &#8220;interested stockholder&#8221;) in advance, or unless the combination is approved by the board of directors and sixty
percent of the corporation&#8217;s voting power not beneficially owned by the interested stockholder, its affiliates and associates. Further,
in the absence of prior approval certain restrictions may apply even after such two year period. However, these statutes do not apply
to any combination of a corporation and an interested stockholder after the expiration of four years after the person first became an
interested stockholder. For purposes of these statutes, an &#8220;interested stockholder&#8221; is any person who is (1) the beneficial
owner, directly or indirectly, of ten percent or more of the voting power of the outstanding voting shares of the corporation, or (2)
an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly,
of ten percent or more of the voting power of the then outstanding shares of the corporation. The definition of the term &#8220;combination&#8221;
is sufficiently broad to cover most significant transactions between a corporation and an &#8220;interested stockholder.&#8221; These
statutes generally apply to Nevada corporations with 200 or more stockholders of record. However, a Nevada corporation may elect in its
articles of incorporation not to be governed by these particular laws, but if such election is not made in the corporation&#8217;s original
articles of incorporation, the amendment (1) must be approved by the affirmative vote of the holders of stock representing a majority
of the outstanding voting power of the corporation not beneficially owned by interested stockholders or their affiliates and associates,
and (2) is not effective until 18 months after the vote approving the amendment and does not apply to any combination with a person who
first became an interested stockholder on or before the effective date of the amendment. We did not make such an election in our original
articles of incorporation and have not amended our articles of incorporation to so elect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nevada&#8217;s &#8220;acquisition of controlling interest&#8221; statutes
(NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition of a controlling interest in certain Nevada corporations.
These &#8220;control share&#8221; laws provide generally that any person that acquires a &#8220;controlling interest&#8221; in certain
Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore
such voting rights. Our bylaws provide that these statutes do not apply to us or any acquisition of our common stock. Absent such provision
in our bylaws, these laws would apply to us as of a particular date if we were to have 200 or more stockholders of record (at least 100
of whom have addresses in Nevada appearing on our stock ledger at all times during the 90 days immediately preceding that date) and do
business in the State of Nevada directly or through an affiliated corporation, unless our articles of incorporation or bylaws in effect
on the tenth day after the acquisition of a controlling interest provide otherwise. These laws provide that a person acquires a &#8220;controlling
interest&#8221; whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the NRS,
would enable that person to exercise (1) one fifth or more, but less than one third, (2) one third or more, but less than a majority or
(3) a majority or more, of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of these
thresholds, shares which it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the
date when the acquiring person acquired or offered to acquire a controlling interest become &#8220;control shares&#8221; to which the
voting restrictions described above apply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NRS 78.139 also provides that directors may resist a change or potential
change in control of the corporation if the board of directors determines that the change or potential change is opposed to or not in
the best interest of the corporation upon consideration of any relevant facts, circumstances, contingencies or constituencies pursuant
to NRS 78.138(4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, our authorized but unissued shares of common stock are
available for our Board of Directors to issue without stockholder approval. We may use these additional shares for a variety of corporate
purposes, including future public or private offerings to raise additional capital, corporate acquisitions and employee benefit plans.
The existence of our authorized but unissued shares of common stock could render more difficult or discourage an attempt to obtain control
of our company by means of a proxy contest, tender offer, merger or other transaction. Our authorized but unissued shares may be used
to delay, defer or prevent a tender offer or takeover attempt that a stockholder might consider in its best interest, including those
attempts that might result in a premium over the market price for the shares held by our stockholders. The Board of Directors is also
authorized to adopt, amend or repeal our Bylaws, which could delay, defer or prevent a change in control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Nasdaq Listing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on The Nasdaq Capital Market under the symbol
&#8220;AEMD.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transfer Agent</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The transfer agent and registrar for our common stock is Computershare
Investor Services. The transfer agent&#8217;s address is P.O. Box 30170, College Station, TX 77842.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s1_009"></span><b>DESCRIPTION OF THE SECURITIES WE ARE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">We are offering (i) up to 4,651,162
shares of our common stock or pre-funded warrants and (ii) warrants to purchase up to an aggregate of 4,651,162 shares
of our common stock. Each share of common stock or&#160;pre-funded&#160;warrant is being sold together with a warrant to purchase
one share of common stock. The shares of common stock or&#160;pre-funded&#160;warrants and accompanying warrants will be issued
separately. We are also registering the shares of common stock issuable from time to time upon exercise of
the&#160;pre-funded&#160;warrants and warrants offered hereby.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The material terms and provisions of our common stock and each other
class of our securities which, if designated and issued, qualifies or limits our common stock are described under the caption &#8220;Description
of Capital Stock&#8221; in this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Pre-Funded&#160;Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The following summary of certain terms and
provisions of the&#160;pre-funded&#160;warrants that are being offered hereby is not complete and is subject to, and qualified in its
entirety by the provisions of, the&#160;pre-funded&#160;warrant. Prospective investors should carefully review the terms and provisions
of the form of&#160;pre-funded&#160;warrant for a complete description of the terms and conditions of the&#160;pre-funded&#160;warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The term&#160;&#8220;pre-funded&#8221;&#160;refers
to the fact that the purchase price of each&#160;pre-funded&#160;warrant, at closing, will equal the price per share at which shares of
our common stock and accompanying warrants to purchase common stock are being sold to the public in this offering, minus $0.001, and the
exercise price of each&#160;pre-funded&#160;warrant will equal $0.001 per share of common stock. The purpose of the&#160;pre-funded&#160;warrants
is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, upon election of the holder,
9.99%) of our outstanding common stock following the consummation of this offering the opportunity to invest capital into us without triggering
their ownership restrictions, by receiving&#160;pre-funded&#160;warrants in lieu of our common stock to the extent it would result in
such ownership of more than 4.99% (or 9.99%), and receive the ability to purchase the shares underlying the&#160;pre-funded&#160;warrants
at such nominal price at a later date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Duration</i>. The&#160;pre-funded&#160;warrants
offered hereby will entitle the holders thereof to purchase shares of our common stock at a nominal exercise price of $0.001 per share,
commencing immediately on the date of issuance. The&#160;pre-funded&#160;warrants do not expire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Exercise Limitation.</i>&#160;A holder
will not have the right to exercise any portion of the&#160;pre-funded&#160;warrant if the holder (together with its affiliates and certain
related parties) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of shares of our common
stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms
of the&#160;pre-funded&#160;warrants. However, any holder may increase or decrease such percentage, provided that any increase will not
be effective until the 61st day after notice of such election is provided to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Exercise Price.</i>&#160;The&#160;pre-funded&#160;warrants
will have an exercise price of $0.001 per share. The exercise price is subject to appropriate adjustment in the event of certain stock
dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also
upon any distributions of assets, including cash, stock or other property to our stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Transferability.</i>&#160;Subject to applicable
laws, the&#160;pre-funded&#160;warrants may be offered for sale, sold, transferred or assigned without our consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Exchange Listing.</i>&#160;There is no
established trading market for the&#160;pre-funded&#160;warrants and we do not expect a market to develop. In addition, we do not intend
to apply for the listing of the&#160;pre-funded&#160;warrants on any national securities exchange or other trading market. Without an
active trading market, the liquidity of the&#160;pre-funded&#160;warrants will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Fundamental Transactions</i>.&#160;If
a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and may exercise every right
and power that we may exercise and will assume all of our obligations under the&#160;pre-funded&#160;warrants with the same effect as
if such successor entity had been named in the&#160;pre-funded&#160;warrant itself. If holders of our common stock are given a choice
as to the securities, cash or property to be received in a fundamental transaction, then the holder shall be given the same choice as
to the consideration it receives upon any exercise of the&#160;pre-funded&#160;warrant following such fundamental transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Rights as a Stockholder.</i>&#160;Except
as otherwise provided in the&#160;pre-funded&#160;warrants or by virtue of such holder&#8217;s ownership of shares of our common stock,
the holder of a&#160;pre-funded&#160;warrant does not have the rights or privileges of a holder of our common stock, including any voting
rights, until the holder exercises the&#160;pre-funded&#160;warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following summary of certain terms and provisions of the warrants
offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the warrant, the form of which has
been filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review
the terms and provisions of the form of warrant for a complete description of the terms and conditions of the warrants. <span style="background-color: white">In
addition, the terms of the warrant to be issued to the placement agent will generally be the same as the warrants issued to investors
in this offering, except that such warrant will not be exercisable for six months following the </span>effective date of the registration
statement of which this prospectus forms a part<span style="background-color: white">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Form.</i> The warrants will be issued as individual warrant agreements
to the investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exercisability.</i> The warrants are exercisable at any time after
their original issuance, expected to be April&#160;&#160;&#160;&#160;, 2024, and at any time up to the date that is five years
after their original issuance. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us
a duly executed exercise notice <span style="background-color: white">and, at any time a registration statement registering the issuance
of the shares of common stock underlying the warrants under the Securities Act is effective and available for the issuance of such shares,
or an exemption from registration under the Securities Act is available for the issuance of such shares</span>, by payment in full in
immediately available funds for the number of shares of common stock purchased upon such exercise. <span style="background-color: white">If
a registration statement registering the issuance of the shares of common stock underlying the warrants under the Securities Act is not
effective or available and an exemption from registration under the Securities Act is not available for the issuance of such shares,
the</span> holder may, in its sole discretion, elect to exercise the warrant through a cashless exercise, in which case the holder would
receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the warrant. No
fractional shares of common stock will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will
pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exercise Limitation. </i>A holder will not have the right to exercise
any portion of the warrant if the holder (together with its affiliates and certain related parties) would beneficially own in excess of
4.99% (or, upon election of the holder, 9.99%) of the number of shares of our common stock outstanding immediately after giving effect
to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase
or decrease such percentage, provided that any increase will not be effective until the 61st day after notice of such election is provided
to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exercise Price.</i> The warrants will have an exercise price of
$ &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;per share. The exercise price is subject
to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications
or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our
stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Transferability.</i> Subject to applicable laws, the warrants may
be offered for sale, sold, transferred or assigned without our consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Exchange Listing.</i> There is no established trading market for
the warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the warrants on any national
securities exchange or other trading market. Without an active trading market, the liquidity of the warrants will be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Fundamental Transactions.</i> If a fundamental transaction occurs,
then the successor entity will succeed to, and be substituted for us, and may exercise every right and power that we may exercise and
will assume all of our obligations under the warrants with the same effect as if such successor entity had been named in the warrant itself.
If holders of our common stock are given a choice as to the securities, cash or property to be received in a fundamental transaction,
then the holder shall be given the same choice as to the consideration it receives upon any exercise of the warrant following such fundamental
transaction. In the event of a fundamental
transaction  the holders of the warrants shall only be entitled
to receive from us or any successor entity, as of the date of consummation of such fundamental transaction, the same type or form of consideration
(and in the same proportion) as if the holder exercised the warrant upon such fundamental transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Rights as a Stockholder.</i> Except as otherwise provided in the
warrants or by virtue of such holder&#8217;s ownership of shares of our common stock, the holder of a warrant does not have the rights
or privileges of a holder of our common stock, including any voting rights, until the holder exercises the warrant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s1_010"></span><b>PLAN OF DISTRIBUTION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an engagement agreement, dated as of February 28,
2024, we have engaged Maxim Group LLC, or the placement agent, to act as our exclusive placement agent to solicit offers to purchase
the securities offered pursuant to this prospectus on a reasonable best-efforts basis. The engagement agreement does not give rise
to any commitment by the placement agent to purchase any of our securities, and the placement agent will have no authority to bind
us by virtue of the engagement agreement. The placement agent is not purchasing or selling any of the securities offered by us under
this prospectus, nor is it required to arrange for the purchase or sale of any specific number or dollar amount of securities. The
placement agent does not guarantee that it will be able to raise new capital in any prospective offering. This offering will
terminate
on&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
, 2024, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have
one closing for all the securities purchased in this offering. The combined public offering price per share of common stock (or
pre-funded warrant) and accompanying warrant will be fixed for the duration of this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will enter into a securities purchase agreement directly with certain
institutional investors, at such investor&#8217;s option, which purchase our securities in this offering. Investors that do not enter
into a securities purchase agreement shall rely solely on this prospectus in connection with the purchase of our securities in this offering.
There is no minimum number of securities or amount of proceeds that is a condition to closing of this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Fees and Expenses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows the p<span style="background-color: white">er
share and accompanying warrant and per&#160;pre-funded&#160;warrant and accompanying warrant</span> and total placement agent fees we
will pay in connection with the sale of the securities in this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Per Share and <br/>
Accompanying Warrant</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Per Pre-Funded</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Warrant and</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Accompanying Warrant</b></p>
</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Placement Agent Fees</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 13%; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have agreed to pay the placement agent a cash fee equal to 6.5%
of the gross proceeds raised at the closing of this offering. We also agreed to issue warrants to the placement agent for the purchase
of a number of shares of common stock equal to 4% of the total number of shares of common stock issued in this offering. In addition,
we have agreed to reimburse the placement agent for its legal fees and expenses and other out-of-pocket expenses in an amount up to $100,000.
We estimate the total offering expenses of this offering that will be payable by us, excluding the placement agent fees and expenses,
will be approximately $379,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Placement Agent Warrants</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In addition, we have agreed to issue to the
placement agent or its designees warrants to purchase up to 186,046 shares of common stock (which represents 4% of the aggregate
number of shares of common stock issued in this offering) with an exercise price of $&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
per share (representing 100% of the combined public offering price per share of common stock (or pre-funded warrant) and accompanying
warrant in this offering). The placement agent warrants will be non-exercisable for six (6) months after the date of the closing and will
expire five years after the commencement of sales of the offering. The form of the placement agent warrants has been included as an exhibit
to this registration statement of which this prospectus is a part.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Lock-up&#160;Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We and each of our officers and directors have agreed with the placement
agent to be subject to a&#160;lock-up&#160;period of 90 days following the date of closing of the offering pursuant to this prospectus.
This means that, during the applicable&#160;lock-up period, we and such persons may not offer for sale, contract to sell, sell, distribute,
grant any option, right or warrant to purchase, pledge, hypothecate or otherwise dispose of, directly or indirectly, any of our shares
of common stock or any securities convertible into, or exercisable or exchangeable for, shares of common stock, subject to customary exceptions.
The placement agent may waive the terms of these lock-up agreements in its sole discretion and without notice. In addition, we have agreed
to not issue any securities that are subject to a price reset based on the trading prices of our common stock or upon a specified or contingent
event in the future or enter into any agreement to issue securities at a future determined price for a period of one year following the
closing date of this offering. The placement agent may waive this prohibition in its sole discretion and without notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Regulation M</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The placement agent may be deemed to be an underwriter within the meaning
of Section&#160;2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the securities
sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter,
the placement agent would be required to comply with the requirements of the Securities Act and the Securities Exchange Act of 1934, as
amended, or the Exchange Act, including, without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations
may limit the timing of purchases and sales of our securities by the placement agent acting as principal. Under these rules and regulations,
the placement agent (i)&#160;may not engage in any stabilization activity in connection with our securities and (ii)&#160;may not bid
for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under
the Exchange Act, until it has completed its participation in the distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnification</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have agreed to indemnify the placement agent against certain liabilities,
including certain liabilities arising under the Securities Act, or to contribute to payments that the placement agent may be required
to make for these liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Determination of Offering Price&#160;and&#160;Warrant Exercise Price</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The actual offering price of the securities we are offering has been
negotiated between us&#160;and the investors in the offering&#160;based on the trading of our shares of common stock prior to the offering,
among other things. Other factors considered in determining the public offering price of the securities we are offering include our history
and prospects, the stage of development of our business, our business plans for the future and the extent to which they have been implemented,
an assessment of our management, the general conditions of the securities markets at the time of the offering and such other factors as
were deemed relevant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Electronic Offer, Sale and Distribution of Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A prospectus in electronic format may be made available on the websites
maintained by the placement agent, if any, participating in this offering and the placement agent may distribute prospectuses electronically.
Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement
of which this prospectus forms a part, has not been approved or endorsed by us or the placement agent, and should not be relied upon by
investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other Relationships</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, the placement agent or its affiliates have in the
past or may in the future provide, various advisory, investment and commercial banking and other services to us in the ordinary course
of business, for which they have received and may continue to receive customary fees and commissions. However, except as disclosed in
this prospectus, we have no present arrangements with the placement agent for any further services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Listing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our shares of common stock are listed on The Nasdaq Capital Market
under the symbol &#8220;AEMD.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Offer Restrictions Outside the United States</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Other than in the United States, no action
has been taken by us or the placement agents that would permit a public offering of the securities offered by this prospectus in any jurisdiction
where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly,
nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities
be distributed or published, in any jurisdiction, except under circumstances that will result in compliance with the applicable rules
and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to
observe any restrictions relating to this offering and the distribution of this prospectus. This prospectus does not constitute an offer
to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a
solicitation is unlawful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>European Economic Area</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In relation to each member state of the European
Economic Area, no offer of securities which are the subject of the offering has been, or will be made to the public in that Member State,
other than under the following exemptions under the Prospectus Directive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(a)</td><td>to any legal entity which is a qualified investor as defined in the Prospectus Directive;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(b)</td><td>to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining
the prior consent of the Representatives for any such offer; or</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(c)</td><td>in any other circumstances falling within Article&#160;3(2) of the Prospectus Directive,</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>provided</i>&#160;that no such offer of securities referred to in
(a)&#160;to (c)&#160;above shall result in a requirement for the Company or the placement agent to publish a prospectus pursuant to Article&#160;3
of the Prospectus Directive, or supplement a prospectus pursuant to Article&#160;16 of the Prospectus Directive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Each person located in a Member State to whom any
offer of securities is made or who receives any communication in respect of an offer of securities, or who initially acquires any shares
of our securities will be deemed to have represented, warranted, acknowledged and agreed to and with the placement agent and the Company
that (1)&#160;it is a &#8220;qualified investor&#8221; within the meaning of the law in that Member State implementing Article&#160;2(1)(e)
of the Prospectus Directive; and (2)&#160;in the case of any shares of our securities acquired by it as a financial intermediary as that
term is used in Article&#160;3(2) of the Prospectus Directive, the securities acquired by it in the offer have not been acquired on behalf
of, nor have they been acquired with a view to their offer or resale to, persons in any Member State other than qualified investors, as
that term is defined in the Prospectus Directive, or in circumstances in which the prior consent of the placement agent has been given
to the offer or resale; or where our securities have been acquired by it on behalf of persons in any Member State other than qualified
investors, the offer of those securities to it is not treated under the Prospectus Directive as having been made to such persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The Company, the placement agent and their respective
affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgments and agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">This prospectus has been prepared on the basis that
any offer of our securities in any Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement
to publish a prospectus for offers of shares. Accordingly, any person making or intending to make an offer in that Member State of our
securities which are the subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation
arises for the Company or the placement agent to publish a prospectus pursuant to Article&#160;3 of the Prospectus Directive in relation
to such offer. Neither the Company nor the placement agent have authorized, nor do they authorize, the making of any offer of securities
in circumstances in which an obligation arises for the Company or the placement agent to publish a prospectus for such an offer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">For the purposes of this provision, the expression
an &#8220;offer of our securities to the public&#8221; in relation to any of our securities in any Member State means the communication
in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor
to decide to purchase or subscribe for the securities, as the same may be varied in that Member State by any measure implementing the
Prospectus Directive in that Member State, the expression &#8220;Prospectus Directive&#8221; means Directive 2003/71/EC (as amended) and
includes any relevant implementing measure in each Member State. The above selling restriction is in addition to any other selling restrictions
set out below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in the United Kingdom</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">In addition, in the United Kingdom, this document
is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#8220;qualified
investors&#8221;(as defined in the Prospectus Directive) (i)&#160;who have professional experience in matters relating to investments falling within Article&#160;19 (5)&#160;of the Financial Services and Markets Act 2000 (Financial Promotion)
Order 2005, as amended (the &#8220;Order&#8221;) and/or (ii)&#160;who are high net worth companies (or persons to whom it may otherwise
be lawfully communicated) falling within Article&#160;49(2)(a) to (d)&#160;of the Order (all such persons together being referred to as
&#8220;relevant persons&#8221;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant
persons. In the United Kingdom, any investment or investment activity to which this document relates is only available to, and will be
engaged in with, relevant persons.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in Switzerland</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The securities may not be publicly offered in Switzerland
and will not be listed on the SIX Swiss Exchange (&#8220;SIX&#8221;) or on any other stock exchange or regulated trading facility in Switzerland.
This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the
Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing
rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing
material relating to our securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Neither this document nor any other offering or
marketing material relating to the offering, the Company or our securities have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of our securities will not be supervised by, the Swiss Financial
Market Supervisory Authority FINMA (FINMA), and the offer of our securities has not been and will not be authorized under the Swiss Federal
Act on Collective Investment Schemes (&#8220;CISA&#8221;). The investor protection afforded to acquirers of interests in collective investment
schemes under the CISA does not extend to acquirers of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in the Dubai International Financial
Centre</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">This prospectus relates to an Exempt Offer in accordance
with the Offered Securities Rules of the Dubai Financial Services Authority (&#8220;DFSA&#8221;). This prospectus is intended for distribution
only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other
person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved
this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The securities
to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities
offered should conduct their own due diligence on the securities. If you do not understand the contents of this prospectus you should
consult an authorized financial advisor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in Australia</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">No placement document, prospectus, product disclosure
statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (&#8220;ASIC&#8221;),
in relation to the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus does not constitute a prospectus, product disclosure
statement or other disclosure document under the Corporations Act 2001 (the &#8220;Corporations Act&#8221;) and does not purport to include
the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Any offer in Australia of our securities may only
be made to persons (the &#8220;Exempt Investors&#8221;) who are &#8220;sophisticated investors&#8221; &#8203;(within
the meaning of section 708(8) of the Corporations Act), &#8220;professional investors&#8221; &#8203;(within the
meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations
Act so that it is lawful to offer the securities without disclosure to investors under Chapter 6D of the Corporations Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The securities applied for by Exempt Investors in
Australia must not be offered for sale in Australia in the period of 12&#160;months after the date of allotment under the offering, except
in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption
under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter
6D of the Corporations Act. Any person acquiring our securities must observe such Australian on-sale restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">This prospectus contains general information only
and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not
contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether
the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice
on those matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in Hong Kong</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The securities have not been offered or sold and
will not be offered or sold in Hong Kong, by means of&#160;any document, other than (a)&#160;to &#8220;professional investors&#8221; as
defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&#160;in other
circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies Ordinance (Cap.&#160;32)
of Hong&#160;Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No&#160;advertisement, invitation
or document relating to the securities has been or may be issued or has been or may be in the possession of any person for the purposes
of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the
public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to securities which
are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in
the Securities and Futures Ordinance and any rules made under that Ordinance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in Japan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The securities have not been and will not be registered
under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended) and, accordingly, will not be offered or sold,
directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly,
in Japan or to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated
by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#8220;Japanese
Person&#8221; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in Singapore</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">This prospectus has not been registered as a prospectus
with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer
or sale, or invitation for subscription or purchase, of securities may not be circulated or distributed, nor may the securities be offered
or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore
other than (i)&#160;to an institutional investor under Section&#160;274 of the Securities and Futures Act, Chapter 289 of Singapore (the
&#8220;SFA&#8221;), (ii)&#160;to a relevant person pursuant to Section&#160;275(1), or any person pursuant to Section&#160;275(1A), and
in accordance with the conditions specified in Section&#160;275, of the SFA, or (iii)&#160;otherwise pursuant to, and in accordance with
the conditions of, any other applicable provision of the SFA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Where the securities are subscribed or purchased
under Section&#160;275 of the SFA by a relevant person which is:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(a)</td><td>a corporation (which is not an accredited investor (as defined in Section&#160;4A of the SFA)) the sole business of which is to hold
investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(b)</td><td>a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust
is an individual who is an accredited investor, securities (as defined in Section&#160;239(1) of the SFA) of that corporation or the beneficiaries&#8217;
rights and interest (howsoever described) in that trust shall not be transferred within six&#160;months after that corporation or that
trust has acquired the securities pursuant to an offer made under Section&#160;275 of the SFA except:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(a)</td><td>to an institutional investor or to a relevant person defined in Section&#160;275(2) of the SFA, or to any person arising from an offer
referred to in Section&#160;275(1A) or Section&#160;276(4)(i)(B) of the SFA;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(b)</td><td>where no consideration is or will be given for the transfer;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(c)</td><td>where the transfer is by operation of law;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(d)</td><td>as specified in Section&#160;276(7) of the SFA; or</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">(e)</td><td>as specified in Regulation&#160;32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&#160;2005
of Singapore.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in Canada</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The securities may be sold only to purchasers purchasing,
or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106&#160;<i>Prospectus Exemptions</i>&#160;or
subsection&#160;73.3(1) of the&#160;<i>Securities Act</i>&#160;(Ontario), and are permitted clients, as defined in National Instrument
31-103&#160;<i>Registration Requirements, Exemptions and Ongoing Registrant Obligations</i>. Any resale of&#160;the securities must be
made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Securities legislation in certain provinces or territories
of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains
a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions
of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">Pursuant to section 3A.3 (or, in the case of securities
issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105&#160;<i>Underwriting
Conflicts</i>&#160;(<b>NI 33-105</b>), the placement agent is not required to comply with the disclosure requirements of NI 33-105 regarding
underwriter conflicts of interest in connection with this offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Notice to Prospective Investors in Israel</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">The securities offered by this prospectus have not
been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale
in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus.
The ISA has not issued permits, approvals or licenses in connection with this offering or publishing the prospectus; nor has it authenticated
the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being
offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions
on transferability and must be effected only in compliance with the Israeli securities laws and regulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s1_011"></span><b>LEGAL MATTERS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The validity of the shares of common stock being offered by this prospectus
will be passed upon for us by Brownstein Hyatt Farber Schreck, LLP. Certain legal matters in connection with the offering and the enforceability
of the warrants and pre-funded warrants being offered by this prospectus will be passed upon for us by Cooley LLP. The placement agent
is being represented by Pryor Cashman LLP, New York, New York.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s1_012"></span><b>EXPERTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements of Aethlon Medical, Inc. for
the year ended March&#160;31, 2023 incorporated by reference in this Registration Statement and Prospectus have been so incorporated in
reliance on the report of Baker Tilly US, LLP, an independent registered public accounting firm, given on the authority of said firm as
experts in auditing and accounting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="s1_013"></span><b>MARKET AND INDUSTRY DATA</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise indicated, information contained in this prospectus
concerning the medical device industry, including our market opportunity, is based on information from independent industry analysts,
third-party sources and management estimates. Management estimates are derived from publicly available information released by independent
industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made by us based on
such data and our knowledge of such industry and market, which we believe to be reasonable. In addition, while we believe the market opportunity
information included in this prospectus is generally reliable and is based on reasonable assumptions, such data involves risks and uncertainties
and are subject to change based on various factors, including those discussed under the heading &#8220;<a href="#s1_004">Risk Factors</a>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s1_014"></span>WHERE YOU CAN FIND ADDITIONAL INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have filed with the SEC a registration statement on Form S-1 under
the Securities Act with respect to the securities being offered by this prospectus. This prospectus does not contain all of the information
in the registration statement and its exhibits. For further information with respect to us and the securities offered by this prospectus,
we refer you to the registration statement and its exhibits. Statements contained in this prospectus as to the contents of any contract
or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other
document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You can read our SEC filings, including the registration statement,
over the Internet at the SEC&#8217;s website at www.sec.gov. You may also request a copy of these filings, at no cost, by writing us at
11555 Sorrento Valley Road, Suite 203, San Diego, California 92121 or telephoning us at (619) 941-0360.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to the information and periodic reporting requirements
of the Exchange Act, and we file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy
statements and other information are available at the website of the SEC referred to above. We maintain a website at www.aethlonmedical.com.
You may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports
filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably
practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed
through, our website is not incorporated by reference in, and is not part of, this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="s1_015"></span>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEC allows us to &#8220;incorporate by reference&#8221; information
from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents.
The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information
incorporated by reference that we filed with the SEC prior to the date of this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We incorporate by reference into this prospectus and the registration
statement of which this prospectus is a part the information or documents listed below (except in each case the information contained
in such document to the extent &#8220;furnished&#8221; and not &#8220;filed&#8221;) that we have filed with the SEC:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our Annual Report on <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823004487/aethlon_i10k-33123.htm">Form 10-K</a> for the fiscal year ended March&#160;31, 2023, filed with the SEC on June 28, 2023;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our definitive proxy statement on <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823005117/aethlon_def14a.htm">Schedule 14A</a>, filed with the SEC on July &#160;27, 2023;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our Quarterly Reports on Form 10-Q for the quarterly periods ended June&#160;30, 2023, September&#160;30, 2023 and December 31, 2023
filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823005524/aethlon_i10q-063023.htm">August&#160; 10, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823008142/aethlon_i10q-093023.htm">November&#160;14, 2023</a>, and <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316824000993/aethlon_i10q-123123.htm">February&#160;14, 2024</a>, respectively;</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>our Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823002609/aethlon_8k.htm">April 25, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823004695/aethlon_8k.htm">July 6, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823006511/aethlon_8k.htm">September 18, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823006959/aethlon_8k.htm">October 4, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823007912/aethlon_8k.htm">November 13, 2023</a>, and <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823008454/aethlon_8k.htm">November 27, 2023</a>, as amended by the Form 8-K/A filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823009061/aethlon_8ka.htm">December 22, 2023</a>; and</td></tr>
<tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td>the description of our common stock, which is registered under Section&#160;12 of the Exchange Act, in our registration statement
on <a href="https://www.sec.gov/Archives/edgar/data/882291/000101968715002644/aethlon_8a12b.htm">Form 8-A</a>, filed with the SEC on July 8, 2015, including any amendments or reports filed for the purpose of updating such description.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, all documents subsequently filed by us pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offering (excluding any information furnished rather than
filed) shall be deemed to be incorporated by reference into this prospectus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will provide to each person, including any beneficial owners, to
whom a prospectus is delivered, a copy of any or all of the reports or documents that have been incorporated by reference in the prospectus
contained in the registration statement but not delivered with the prospectus. We will provide these reports or documents upon written
or oral request at no cost to the requester. You should direct any written requests for documents to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Aethlon Medical, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">11555 Sorrento Valley Road, Suite 203</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, California 92121</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Telephone: (619) 941-0360</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You also may access these filings on our website at www.aethlonmedical.com.
Information contained on or accessible through our website is not a part of this prospectus or the registration statement of which it
forms a part, and the inclusion of our website address in this prospectus is an inactive textual reference only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In accordance with Rule 412 of the Securities Act, (i)&#160;any statement
contained in a document incorporated by reference herein shall be deemed modified or superseded to the extent that a statement contained
herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes
such statement, and (ii)&#160;any statement contained in a document that is deemed to be incorporated by reference herein after the date
of this prospectus may modify or replace existing statements contained herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Aethlon Medical, Inc.</b></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>Up to 4,651,162
Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>Pre-Funded Warrants
to Purchase up to 4,651,162 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>Warrants to Purchase
up to 4,651,162 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>Placement Agent
Warrants to Purchase up to 186,046 Shares of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>Shares of Common
Stock Issuable upon the Exercise of the Warrants, Pre-Funded Warrants and Placement Agent Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>&#160;</b></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>PROSPECTUS</b></span><b>
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt; background-color: white"><b>Maxim
Group LLC</b></span></p>

<p style="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 24pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><div style="border-top: black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>April&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2024 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PART II </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INFORMATION NOT REQUIRED IN PROSPECTUS </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-size: 10pt"><b>Item&#160;13.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>Other Expenses of Issuance and Distribution. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth the costs and expenses, other than placement
agent fees, paid or payable by Aethlon Medical, Inc., or the Registrant, in connection with the sale and distribution of the securities
being registered. All amounts are estimated except the SEC registration fee and the Financial Industry Authority, Inc., or FINRA, filing
fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold">Item</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">SEC registration fee</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,409</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">FINRA filing fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,948</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Printing and engraving expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transfer agent fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Miscellaneous fees and expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,143</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">379,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-size: 10pt"><b>Item&#160;14.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>Indemnification of Directors and Officers. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are incorporated in Nevada. Section 78.7502(1) of the Nevada Revised
Statutes, or NRS, provides that a corporation may indemnify, pursuant to that statutory provision, any person who was or is a party or
is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative
or investigative (other than an action by or in the right of the corporation) by reason of the fact that he is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent
of another corporation or other enterprise or as a manager of a limited liability company, against expenses (including attorneys&#8217;
fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action,
suit or proceeding if he is not liable pursuant to NRS 78.138 or if he acted in good faith and in a manner he reasonably believed to be
in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable
cause to believe his or her conduct was unlawful. NRS 78.138(7) provides that, subject to limited statutory exceptions and unless the
articles of incorporation or an amendment thereto (in each case filed on or after October 1, 2003) provide for greater individual liability,
a director or officer is not individually liable to the corporation or its stockholders or creditors for any damages as a result of any
act or failure to act in his or her capacity as a director or officer unless the presumption established by NRS 78.138(3) has been rebutted
and it is proven that (i) his or her act or failure to act constituted a breach of his or her fiduciary duties as a director or officer,
and (ii) such breach involved intentional misconduct, fraud or a knowing violation of the law.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 29; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NRS 78.7502(2) permits a corporation to indemnify, pursuant to that
statutory provision, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action
or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of
the capacities set forth above against expenses, including amounts paid in settlement and attorneys&#8217; fees actually and reasonably
incurred by him or her in connection with the defense or settlement of such action or suit if he acted under similar standards, except
that no indemnification pursuant to NRS 78.7502 may be made in respect of any claim, issue or matter as to which such person shall have
been adjudged by a court of competent jurisdiction, after any appeals taken therefrom, to be liable to the corporation or for amounts
paid in settlement to the corporation, unless and only to the extent that the court in which such action or suit was brought or other
court of competent jurisdiction determines that, in view of all the circumstances of the case, such person is fairly and reasonably entitled
to indemnity for such expenses as the court deems proper. NRS 78.751(1) provides that a corporation shall indemnify any person who is
a director, officer, employee or agent of the corporation, against expenses actually and reasonably incurred by the person in connection
with defending an action (including, without limitation, attorney&#8217;s fees), to the extent that the person is successful on the merits
or otherwise in defense of any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or
investigative, including, without limitation, an action by or in the right of the corporation, by reason of the fact that the person is
or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director,
officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise or as a manager of a limited
liability company, or any claim, issue or matter in such action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NRS 78.751 provides that the indemnification pursuant to NRS 78.7502
shall not be deemed exclusive or exclude any other rights to which the indemnified party may be entitled (except that indemnification
may not be made to or on behalf of any director or officer finally adjudged by a court of competent jurisdiction, after exhaustion of
any appeals taken therefrom, to be liable for intentional misconduct, fraud or a knowing violation of the law and such intentional misconduct,
fraud or a knowing violation of the law was material to the cause of action) and that the indemnification shall continue as to directors,
officers, employees or agents who have ceased to hold such positions, and to their heirs, executors and administrators. NRS 78.752 permits
a corporation to purchase and maintain insurance on behalf of a director, officer, employee or agent of the corporation against any liability
asserted against him or her or incurred by him or her in any such capacity or arising out of his or her status as such whether or not
the corporation would have the power to indemnify him or her against such liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Bylaws</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our bylaws include express provisions providing for the indemnification
of our directors and officers to the fullest extent permitted under the NRS, and the mandatory payment by us of expenses incurred by such
persons in defending a civil or criminal action, suit or proceeding in advance of the final disposition of the action, suit or proceeding,
upon receipt of an undertaking by or on behalf of the director or officer to repay the amount if it is ultimately determined that such
person is not entitled to be indemnified by us. Our bylaws also permit us to purchase and maintain insurance or make other financial arrangements
on behalf of any such person for certain liability and expenses, whether or not we have the authority to indemnify such person against
such liability and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liability Insurance</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We maintain directors&#8217; and officers&#8217; liability insurance
covering our directors and officers against expenses and liabilities arising from certain actions to which they may become subject by
reason of having served in such role, including insurance for claims against these persons brought under securities laws. Such insurance
is subject to the coverage amounts, exceptions, deductibles and other conditions set forth in the policy as in effect at the time of a
claim, if any. There is no assurance that we will maintain liability insurance for our directors and officers.</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-size: 10pt"><b>Item&#160;15.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>Recent Sales of Unregistered Securities. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Within the past three years, the Registrant did not sell any unregistered
securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-size: 10pt"><b>Item&#160;16.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>Exhibits and Financial Statement Schedules. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>(a) Exhibits </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are being filed with this Registration Statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>(b) Financial Statement Schedules </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">No financial statement schedules are provided because the information
called for is not required or is shown either in the financial statements or the notes thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Number</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 40%; text-align: center"><span style="font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 10%; text-align: center"><span style="font-size: 10pt"><b>SEC File No.</b></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 6%; text-align: center"><span style="font-size: 10pt"><b>Exhibit <br/>
No.</b></span></td>
    <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 10%; text-align: center"><span style="font-size: 10pt"><b>Filed <br/>
Herewith</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316822006480/aethlon_ex0301.htm">Articles of Incorporation, as amended.</a></span></td>
    <td><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">001-37487</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">September 19, 2022</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819002910/aethlon_8k-ex0301.htm">Amended and Restated Bylaws of the Company.</a></span></td>
    <td><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">001-37487</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">3.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">September 12, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt">Reference is made to Exhibits 3.1 and 3.2.</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/882291/000101968714004876/aethlon_s1-ex0401.htm">Form of Common Stock Certificate.</a></span></td>
    <td><span style="font-size: 10pt">S-1</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">333-201334</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">December 31, 2014</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819003944/aethlon_ex0414.htm">Form of Warrant to Purchase Common Stock.</a></span></td>
    <td><span style="font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">333-234712</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">4.14</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">December 11, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819003944/aethlon_ex0415.htm">Form of Underwriter Warrant.</a></span></td>
    <td><span style="font-size: 10pt">S-1/A</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">333-234712</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">4.15</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">December 11, 2019</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316820000188/aethlon_ex0401.htm">Form of Common Stock Purchase Warrant.</a></span></td>
    <td><span style="font-size: 10pt">8-K</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">001-37487</span></td>
    <td colspan="2" style="text-align: center"><span style="font-size: 10pt">4.1</span></td>
    <td style="text-align: center"><span style="font-size: 10pt">January 17, 2020</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td colspan="2"><a href="aethlon_ex0406.htm"><span style="font-size: 10pt">Form of Warrant to Purchase Common Stock.</span></a></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">4.7</span></td>
    <td>&#160;</td>
    <td colspan="2"><a href="aethlon_ex0407.htm"><span style="font-size: 10pt">Form of Pre-Funded Warrant to Purchase Common Stock</span></a></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">4.8</span></td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><a href="aethlon_ex0408.htm">Form of Placement Agent Warrant to Purchase Common Stock</a></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">5.1</span></td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><a href="aethlon_ex0501.htm">Opinion of Brownstein Hyatt Farber Schreck, LLP.</a></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td><span style="font-size: 10pt">5.2</span></td>
    <td>&#160;</td>
    <td colspan="2"><a href="aethlon_ex0502.htm"><span style="font-size: 10pt">Opinion of Cooley LLP.</span></a></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>

<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.1++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316822001002/aethlon_ex1002.htm">Aethlon Medical, Inc. Amended and Restated Non-Employee Director Compensation Policy, as Modified on February 10, 2022</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.2</td>
    <td style="text-align: center">February 14, 2022</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.2++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1003.htm">Employment Agreement, by and between Aethlon Medical, Inc. and James Frakes, dated December 12, 2018</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.3</td>
    <td style="text-align: center">February 1, 2019</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.3++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1004.htm">Form of Indemnification Agreement for Officers and Directors.</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.4</td>
    <td style="text-align: center">February 11, 2019</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Number</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 40%"><span style="font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 6%"><span style="font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 10%"><span style="font-size: 10pt"><b>SEC File No.</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 6%"><span style="font-size: 10pt"><b>Exhibit <br/>
No.</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 10%"><span style="font-size: 10pt"><b>Filed <br/>
Herewith</b></span></td></tr>

  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.4++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1005.htm">Form of Option Grant Agreement for Officers and Directors</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.5</td>
    <td style="text-align: center">February 11, 2019</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.5++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1006.htm">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for Directors.</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.6</td>
    <td style="text-align: center">February 11, 2019</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.6++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819000327/aethlon_10q-ex1007.htm">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement for Executives.</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.7</td>
    <td style="text-align: center">February 11, 2019</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.7</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316819003664/aethlon_ex-1027.htm">Assignment Agreement, by and between Aethlon Medical, Inc. and London Health Sciences Center Research Inc., dated November 7, 2006.</a></td>
    <td>S-1</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.27</td>
    <td style="text-align: center">November 15, 2019</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.8++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316822006480/aethlon_ex9901.htm">Aethlon Medical, Inc. 2020 Equity Incentive Plan, Form of Restricted Stock Grant, Form of Option Grant and Agreement.</a></td>
    <td>8-K</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">99.1</td>
    <td style="text-align: center">September 19, 2022</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.9++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316820003665/aethlon_8k-ex1002.htm">Employment Agreement between the Company and Dr. Fisher, dated October 30, 2020.</a></td>
    <td>8-K</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.2</td>
    <td style="text-align: center">November 3, 2020</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.10</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316821000475/aethlon_ex1003.htm">Lease, by and between the Company and San Diego Inspire 1, LLC. and San Diego Inspire 2, LLC, effective December 7, 2020.</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.3</td>
    <td style="text-align: center">February 10, 2021</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.11++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316821000475/aethlon_ex1005.htm">Executive Employment Agreement between the Company and Guy Cipriani, dated January 1, 2021.</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.5</td>
    <td style="text-align: center">February 10, 2021</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.12++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316821000475/aethlon_ex1006.htm">Executive Employment Agreement between the Company and Steven P. LaRosa, MD, dated January 4, 2021.</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.6</td>
    <td style="text-align: center">February 10, 2021</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.13++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823000822/aethlon_ex1001.htm">Executive Employment Agreement, by and between Aethlon Medical, Inc. and Lee D. Arnold, Ph.D., dated February 1, 2023.</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.1</td>
    <td style="text-align: center">February 13, 2023</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.14</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316821005369/aethlon_ex1001.htm">Lease between Aethlon Medical, Inc. and San Diego Inspire 5, LLC, effective October 27, 2021.</a></td>
    <td>10-Q</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.1</td>
    <td style="text-align: center">November 9, 2021</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.15</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316822001925/aethlon_ex0101.htm">At the Market Offering Agreement, dated March 24, 2022, by and between Aethlon Medical, Inc. and H.C. Wainwright &amp; Co., LLC</a>.</td>
    <td>8-K</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">1.1</td>
    <td style="text-align: center">March 24, 2022</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.16++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823004487/aethlon_ex1018.htm">Amendment No. 1 to Executive Employment Agreement, by and between Aethlon Medical, Inc. and Lee D. Arnold, Ph.D., dated May 1, 2023.</a></td>
    <td>10-K</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.18</td>
    <td style="text-align: center">June 28, 2023</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2"><p style="margin-top: 0; margin-bottom: 0"></p>
                    <p style="margin-top: 0; margin-bottom: 0">&#160;<br/></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.17++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823008454/aethlon_ex1001.htm">Separation Agreement between the Company and Dr. Fisher, effective as of November 27, 2023.</a></td>
    <td>8-K</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.1</td>
    <td style="text-align: center">November 27, 2023</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.18++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823009061/aethlon_ex1001.htm">Amendment No. 1 to Executive Employment Agreement, effective as of November 7, 2023, by and between the Company and James B. Frakes.</a></td>
    <td>8-K</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.1</td>
    <td style="text-align: center">December 22, 2023</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.19++</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823009061/aethlon_ex1002.htm">Amendment No. 1 to Executive Employment Agreement, effective as of November 7, 2023, by and between the Company and Guy F. Cipriani</a></td>
    <td>8-K</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">10.2</td>
    <td style="text-align: center">December 22, 2023</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 7%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Number</b></p></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 40%"><span style="font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 6%"><span style="font-size: 10pt"><b>Form</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 10%"><span style="font-size: 10pt"><b>SEC File No.</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 6%"><span style="font-size: 10pt"><b>Exhibit <br/>
No.</b></span></td>
    <td style="vertical-align: bottom; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 15%"><span style="font-size: 10pt"><b>Date</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 10%"><span style="font-size: 10pt"><b>Filed <br/>
Herewith</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>10.20</td>
    <td>&#160;</td>
    <td colspan="2"><a href="aethlon_ex1020.htm">Form of Securities Purchase Agreement</a></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>21.1</td>
    <td>&#160;</td>
    <td colspan="2"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316823004487/aethlon_ex2101.htm">List of Subsidiaries</a></td>
    <td>10-K</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">001-37487</td>
    <td colspan="2" style="text-align: center">21.1</td>
    <td style="text-align: center">June 28, 2023</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;<br/>
</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>23.1</td>
    <td>&#160;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="aethlon_ex2301.htm">Consent of Independent Registered Public Accounting Firm</a></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>23.2</td>
    <td>&#160;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="aethlon_ex0501.htm">Consent of Brownstein Hyatt Farber Schreck, LLP</a> (included in Exhibit
5.1).</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>23.3</td>
    <td>&#160;</td>
    <td colspan="2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><a href="aethlon_ex0502.htm">Consent of Cooley LLP</a> (included in Exhibit 5.2).</p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">X</td></tr>
<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>24.1*</td>
    <td>&#160;</td>
    <td colspan="2"><p style="margin: 0pt 0; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/882291/000168316824001638/aethlon_s1.htm#s1_poa">Power of Attorney</a> <span style="font-family: Times New Roman, Times, Serif">(reference is made
to signature page)</span></p></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td>107*</td>
    <td>&#160;</td>
    <td colspan="2"><a href="http://www.sec.gov/Archives/edgar/data/882291/000168316824001638/aethlon_ex107.htm">Filing Fee Table<br/></a></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">__________________</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 8px">&#160;</td>
    <td style="width: 16px">*</td>
    <td>&#160;</td>
    <td>Previously filed.</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">++</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Indicates management contract or compensatory plan.</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span style="font-size: 10pt"><b>Item&#160;17.</b></span></td>
    <td style="width: 90%"><span style="font-size: 10pt"><b>Undertakings </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned registrant hereby undertakes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) To file, during any period in which offers or sales are being made,
a post-effective amendment to this registration statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) To include any prospectus required by Section&#160;10(a)(3) of
the Securities Act;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ii) To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate,
represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase
or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered)
and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with
the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20&#160;percent change
in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration
statement;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) To include any material information with respect to the plan
of distribution not previously disclosed in the registration statement or any material change to such information in the registration
statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2) That, for the purpose of determining any liability under the Securities
Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the initial <i>bona fide</i> offering thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4) That, for the purpose of determining liability under the Securities
Act to any purchaser: each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other
than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part
of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser
with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement
or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise,
the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by
the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by
the final adjudication of such issue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act, the Registrant
has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California,
on the 5th day of April, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 1in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td colspan="2" style="vertical-align: top"><span style="font-size: 10pt"><br/>
AETHLON MEDICAL, INC.</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1pt solid"><span style="font-size: 10pt">/s/ JAMES B. FRAKES</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="vertical-align: bottom"><span style="font-size: 10pt">James B. Frakes</span></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="vertical-align: bottom"><span style="font-size: 10pt">Interim Chief Executive Officer</span></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt">Chief Accounting Officer</span></td>
    <td>&#160;</td></tr>
  <tr>
    <td style="width: 48%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 23%">&#160;</td>
    <td style="width: 16%">&#160;</td>
    <td style="width: 10%">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act, this Registration
Statement has been signed by the following persons in the capacities and on the dates indicated.</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">/s/ JAMES B. FRAKES</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">James B. Frakes</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt">Interim Chief Executive
    Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt">Chief Financial Officer</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt">Chief Accounting Officer
    and Director</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">April 5, 2024</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">/s/ EDWARD G. BROENNIMAN*</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Edward G. Broenniman</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Chairman and Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">April 5, 2024</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">/s/ NICOLAS GIKAKIS*</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nicolas Gikakis</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">April 5, 2024</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">/s/ ANGELA ROSSETTI*</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Angela Rossetti</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">April 5, 2024</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">/s/ CHETAN S. SHAH*</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chetan S. Shah, M.D.</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="white-space: nowrap; vertical-align: top; text-align: center"><span style="font-size: 10pt">April 5, 2024</span></td></tr>
  <tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr>
    <td colspan="4"><span style="font-size: 10pt">* Pursuant to power of attorney</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 4%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; width: 33%"><span style="font-size: 10pt">/s/ JAMES B. FRAKES</span></td>
    <td style="width: 63%">&#160;</td>
    </tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">James B. Frakes</span></td>
    <td>&#160;</td>
    </tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Attorney in fact</span></td>
    <td>&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 35; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OVK3fMi3korIIiSi1yXHWNIdmd3KPqm/bFOiYWAY7j33CjESa1rpGhnOiyKHIzZtrRxCgRUymgt6R7bZpuBvgVdtHSvj+vcHZuQZ9EwyllJ5obc+tMUyhWgSyjiUU4ijNJnBfCeCr56RqXSJxmlVgzIlHJha1ugUv4aEo+rIUPPqq07IVpNJIR5Hg/wGGcUS9vRQT+KbhTzPRDDqJxBrpnvrXcvOofmSsKyx8XV2oP8bfAD+A0p+ -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>2
<FILENAME>aethlon_ex0406.htm
<DESCRIPTION>FORM OF WARRANT TO PURCHASE COMMON STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><B>Exhibit 4.6</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AETHLON
MEDICAL, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">Warrant Shares: _______</TD>
  <TD STYLE="text-align: right; width: 50%">Initial Exercise Date: [___], 2024</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CUSIP: _______</P>


</TD>
  <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
______________ (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on ______________<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP></SUP></FONT>
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Aethlon Medical, Inc., a Nevada corporation
(the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository
Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially be the sole registered holder of this Warrant, subject to a Holder&rsquo;s
right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence
shall not apply. &ldquo;<U>Warrant Agency Agreement</U>&rdquo; means that certain warrant agency agreement, dated on or about the Initial
Exercise Date, between the Company and the Warrant Agent. &ldquo;<U>Warrant Agent</U>&rdquo; means the Transfer Agent and any successor
warrant agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap"><U>Section
1.</U></FONT></U> <U>Definitions.</U> Capitalized terms used and not otherwise defined herein shall have the meanings set forth in
that certain Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;), dated [___], 2024, among the Company and the
purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap"><U>Section 2.</U></FONT></U>
<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Notwithstanding the
foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this Warrant
held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect exercises
made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction
form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable),
subject to a Holder&rsquo;s right to elect to receive a Definitive Warrant pursuant to the terms of the Warrant Agency Agreement, in which
case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$</B>_____, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> <FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">d)</FONT> <U>Mechanics of Exercise</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">i.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery
of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the
delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of
the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the
Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery
Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing
to $20 per Trading Day on the fifth (5th) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent
that is a participant in the Fast Automated Securities Transfer Program (FAST program) so long as this Warrant remains outstanding and
exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of
the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">ii.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">iii.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by notifying the Warrant
Agent or the Company of such rescission at any time prior to the delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">iv.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">v.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">vi.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">vii.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> <FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">e)</FONT> <U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not affect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any reports or schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or 9.99% at the election of the Holder) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap"><U>Section 3.</U></FONT></U><U>Certain Adjustments.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time while this Warrant
is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other
property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-underline-style: double"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT></FONT><U>Pro Rata Distributions</U>. Except in the case of a Fundamental Transaction to which Section 3(e) below is applicable
or to which a notice under Section 3(g)(ii) below applies, during such time as this Warrant is outstanding, if the Company shall declare
or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way
of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the
time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has
exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">e)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the outstanding common stock of the Company, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock
or 50% or more of the voting power of the outstanding common stock of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor
entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in
writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions
of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to
this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on
the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the
purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and
which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall succeed to, and be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and the Successor Entity may exercise every right and power of the Company and shall assume all of the obligations of the Company under
this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">i.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">ii.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that the Company, in consultation with its legal counsel, determines that any notice provided
in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
shall comply with (i) its disclosure obligations under Regulation FD and (ii) the applicable instructions to Form 8-K. The Holder shall
remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time
during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by
the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap"><U><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap"><U>Section 4.</U></FONT></U></FONT> <U>Transfer of Warrant</U>.

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. <FONT STYLE="text-decoration: double">Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company or Warrant Agent unless the Holder has
assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company or Warrant Agent within three (3)
Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full.</FONT> The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new
Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Warrant Register</U>. The Warrant Agent (or, in the event a Holder elects to receive a Definitive Certificate (as defined in
the Warrant Agency Agreement), the Company) shall register this Warrant, upon records to be maintained by the Warrant Agent (or, in the
event a Holder elects to receive a Definitive Certificate, the Company) for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 1in; float: left; white-space:nowrap"><U>Section 5.</U></FONT>&nbsp;<U>Miscellaneous.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers,
shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City
of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of
New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other
provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, or e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 11555 Sorrento Valley Road, Suite 203, San Diego, CA 92121, Attention: James Frakes, email
address: accountspayable@aethlonmedical.com, or such other facsimile number, email address or address as the Company may specify for such
purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall
be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed
to each Holder at the facsimile number, e-mail address or address of such Holder appearing on the books of the Company. Any notice or
other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not
a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required
to be given. To the extent that the Company, in consultation with its legal counsel, determines that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall comply
with (i) its disclosure obligations under Regulation FD and (ii) the applicable instructions to Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">j)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">k)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">l)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">m)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">n)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">o)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Warrant Agency Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant
is issued subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of
the Warrant Agency Agreement, the provisions of this Warrant shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>AETHLON MEDICAL, Inc.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">To:</FONT>AETHLON
MEDICAL, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name:</P></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>_____________________________________</U></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><U>_____________________________________</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-decoration: none double">Phone
    Number:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-decoration: none double">Email
    Address: </FONT></P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-decoration: underline solid">______________________________________</FONT></P>
    <P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><FONT STYLE="text-decoration: none double">______________________________________</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Dated: _______________ __, ______</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Holder&rsquo;s Signature:<U>_____________________________________</U></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="color: black">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="color: black">Holder&rsquo;s Address:<U>_____________________________________</U></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="color: black">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Warrant Certificate Request Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT CERTIFICATE REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Computershare Investor Services, as Warrant
Agent for Aethlon Medical, Inc. (the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of Common Stock Purchase
Warrants (&ldquo;<U>Warrants</U>&rdquo;) in the form of Global Warrants issued by the Company hereby elects to receive a Warrant Certificate
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25px; text-align: justify; font-size: 10pt">1.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder of Warrants in form of Global Warrants: _____________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">2.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder in Warrant Certificate (if different from name of Holder of Warrants in form of Global Warrants): ________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">3.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Global Warrants: ___________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">4.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants for which Warrant Certificate shall be issued: __________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">5.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Global Warrants after issuance of Warrant Certificate, if any: ___________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">6.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Warrant Certificate shall be delivered to the following address:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed to have surrendered the
number of Warrants in the form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: ______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________________________________________________________</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Global Warrant Request Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GLOBAL WARRANT REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Computershare Investor Services, as Warrant
Agent for Aethlon Medical, Inc. (the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of Common Stock Purchase
Warrants (&ldquo;<U>Warrants</U>&rdquo;) in the form of Warrant Certificates issued by the Company hereby elects to receive a Global Warrant
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25px; text-align: justify; font-size: 10pt">1.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder of Warrants in form of Warrant Certificates: _____________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">2.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder in Global Warrant (if different from name of Holder of Warrants in form of Warrant Certificates): ________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">3.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Warrant Certificates: ___________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">4.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants for which Global Warrant shall be issued: __________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">5.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Warrant Certificates after issuance of Global Warrant, if any: ___________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">6.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Global Warrant shall be delivered to the following address:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Global Warrant Exchange and the issuance of the Global Warrant, the Holder is deemed to have surrendered
the number of Warrants in form of Warrant Certificates in the name of the Holder equal to the number of Warrants evidenced by the Global
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: ______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________________________________________________________</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>3
<FILENAME>aethlon_ex0407.htm
<DESCRIPTION>FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><B>Exhibit 4.7</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AETHLON
MEDICAL</B></FONT><B>, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 54%; font-size: 10pt">Warrant Shares: [<FONT STYLE="font-family: Wingdings">l</FONT>]</TD>
    <TD STYLE="width: 46%; font-size: 10pt; text-align: right">Issue Date and Initial Exercise Date: [<FONT STYLE="font-family: Wingdings">l</FONT>],
    2024</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from <FONT STYLE="text-transform: uppercase">AETHLON MEDICAL</FONT>,
INC., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to [<FONT STYLE="font-family: Wingdings">l</FONT>] shares (as subject
to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under
this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated [<FONT STYLE="font-family: Wingdings">l</FONT>], 2024, among the Company and the
purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise of
Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or
after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of (i) a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;) and
(ii) the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s
check drawn on a United States bank (unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable
Notice of Exercise). No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the
Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three
(3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver
any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. Notwithstanding the foregoing, with respect
to any Notice(s) of Exercise delivered on or prior to 4:00 p.m. (New York City time) on the Trading Date prior to the Initial Exercise
Date, which may be delivered at any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant
Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be
the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case
of a cashless exercise) is received by such Warrant Share Delivery Date. <B>The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder,
the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded to the Company
on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001
per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not
be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any
reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid
exercise price per share of Common Stock under this Warrant shall be $0.001, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless Exercise</U>.
This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder
shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">=&#9;as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading
Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, or (ii)
the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise
is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading
Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">=&#9;the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(X)</TD><TD STYLE="text-align: justify">=&#9;the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with
the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rules or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted for trading on a Trading
Market and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to
its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (c) in all other cases, the
fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Company and reasonably
acceptable to the Purchasers of a majority in interest of the Securities then outstanding, the fees and expenses of which shall be paid
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">d) <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">i. <U>Delivery of
Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent
to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) the Holder has sold the Warrant Shares pursuant to an effective registration statement registering the resale of the Warrant
Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations or any
requirement for the Company to comply with the current public information obligations of Rule 144(c) pursuant to Rule 144 (assuming cashless
exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the
name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the
address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery
to the Company of the Notice of Exercise (and receipt of the aggregate Exercise Price) and (ii) the number of Trading Days comprising
the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (and receipt of the aggregate Exercise Price)
(such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise and receipt of payment of the
aggregate Exercise Price (other than in the case of a cashless exercise), the Holder shall be deemed for all corporate purposes to have
become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares. The Company agrees to maintain a transfer agent that is a participant in the Fast Automated Securities Transfer
Program (FAST program) so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any
Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at
any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s)
by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date
for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
by such Warrant Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 31.5pt">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117.35pt; text-align: justify; text-indent: 31.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">iv. <U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As
to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">v. <U>Charges, Taxes
and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">vi. <U>Closing of
Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant
that are not in compliance with the Beneficial Ownership Limitation, provided this limitation of liability shall not apply if the Holder
has detrimentally relied on outstanding share information provided by the Company or the Transfer Agent. In addition, a determination
as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock,
a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or
annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request
of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be 4.99% (or 9.99% at the election of the Holder) of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase
or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in
no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any
increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to
the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock Dividends
and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which,
for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding
shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of
capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise
of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>[Reserved]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Pro Rata Distributions</U>.
Except in the case of a Fundamental Transaction to which Section 3(e) below is applicable or to which a notice under Section (g)(ii) below
applies, during such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its
assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of more than 50% of the outstanding Common Stock or more than 50% of the voting
power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock or more than 50% of the voting power of the common equity of the Company
(each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction, at the option of the Holder (without regard to the Beneficial Ownership Limitation in Section 2(e) on the exercise of this
Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other
Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at
the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value
of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares
of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the
consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence
of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that
from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other
Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor
Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise
every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations
of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor
Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall
be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient authorized shares
of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Notice to
Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice to
Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock,
(B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize
the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class
or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the
Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or
substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or
property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the
Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear
upon the Warrant Register of the Company, at least three calendar days prior to the applicable record or effective date hereinafter specified,
a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in
the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4. Transfer of
Warrant.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof, this Warrant and all rights
hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant
at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the
form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or
Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant
to the Company on the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new
Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New Warrants</U>.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the issue date and shall be identical with this Warrant except
as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No Rights
as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends or
other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i). Without limiting any rights
of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c), in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss, Theft,
Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to
it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. The Company covenants
that, following the Initial Exercise Date and during the period the Warrant is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who
are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company
covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon
exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. Except and to
the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii. Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public
regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder
in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>AETHLON MEDICAL</B></FONT><B>,
    INC.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%; font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 100%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To: AETHLON
MEDICAL</FONT>, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The undersigned hereby elects
to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment shall take the form
of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; font-size: 10pt; text-align: justify">Name:</TD>
    <TD STYLE="width: 48%; font-size: 10pt; text-align: justify">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Address:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><U>______________________________________</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone Number:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address:</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Signature:_________________________</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Address: _________________________</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.8
<SEQUENCE>4
<FILENAME>aethlon_ex0408.htm
<DESCRIPTION>FORM OF PLACEMENT AGENT WARRANT TO PURCHASE COMMON STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 4.8</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0"><B></B></P>


<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLACEMENT AGENT COMMON STOCK
PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AETHLON
MEDICAL, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: _______&#9;Initial Exercise Date: [___], 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CUSIP: _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and from
time to time from and after the 181<SUP>st</SUP> day (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) immediately following the date of
effectiveness of that certain registration statement on Form S-1 (File No. 333-[ ]) filed by the Company, in accordance with FINRA Rule
5110(g)(1), and through and including the fifty-four month anniversary of the date of effectiveness of that certain registration statement
on Form S-1 (File No. 333-[ ]), which such date is [ ], 202[ ] (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe
for and purchase from Aethlon Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject
to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under
this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&#9;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated [___], 2024, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&#9;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$</B>_____, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics of Exercise</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery
of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the
delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of
the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the
Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery
Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing
to $20 per Trading Day on the fifth (5th) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent
that is a participant in the Fast Automated Securities Transfer Program (FAST program) so long as this Warrant remains outstanding and
exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of
the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by notifying the Warrant
Agent or the Company of such rescission at any time prior to the delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"> e) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not affect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any reports or schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or 9.99% at the election of the Holder) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&#9;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time while this Warrant
is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other
property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-underline-style: double">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT><U>Pro Rata Distributions</U>. Except in the case of a Fundamental Transaction to which Section 3(e) below is applicable
or to which a notice under Section 3(g)(ii) below applies, during such time as this Warrant is outstanding, if the Company shall declare
or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way
of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the
time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has
exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any
Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the outstanding common stock of the Company, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or
50% or more of the voting power of the outstanding common stock of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of
capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the
value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the
other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and the Successor Entity
may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other
Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that the Company, in consultation with its legal counsel, determines that any notice provided
in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
shall comply with (i) its disclosure obligations under Regulation FD and (ii) the applicable instructions to Form 8-K. The Holder shall
remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time
during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by
the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&#9;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. <FONT STYLE="text-decoration: none double">Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company or Warrant Agent unless the
Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company or Warrant Agent within
three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full.</FONT>
The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without
having a new Warrant issued. This Warrant may not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging,
short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person
for a period of 180 days immediately following the date of effectiveness of that certain registration statement on Form S-1 (File No.
333-[ ]) filed by the Company, except as provided in FINRA Rule 5110(g)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Register</U>. The Warrant Agent (or, in the event a Holder elects to receive a Definitive Certificate (as defined in
the Warrant Agency Agreement), the Company) shall register this Warrant, upon records to be maintained by the Warrant Agent (or, in the
event a Holder elects to receive a Definitive Certificate, the Company) for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&#9;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers,
shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City
of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of
New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other
provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, or e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 11555 Sorrento Valley Road, Suite 203, San Diego, CA 92121, Attention: James Frakes, email
address: accountspayable@aethlonmedical.com, or such other facsimile number, email address or address as the Company may specify for such
purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall
be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed
to each Holder at the facsimile number, e-mail address or address of such Holder appearing on the books of the Company. Any notice or
other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not
a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required
to be given. To the extent that the Company, in consultation with its legal counsel, determines that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall comply
with (i) its disclosure obligations under Regulation FD and (ii) the applicable instructions to Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Warrant Agency Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant
is issued subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of
the Warrant Agency Agreement, the provisions of this Warrant shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><BR STYLE="clear: both"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>AETHLON MEDICAL, Inc.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:__________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Title:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;AETHLON
MEDICAL, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">[ ] if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; font-size: 10pt; text-align: justify">Name:</TD>
    <TD STYLE="width: 48%; font-size: 10pt; text-align: justify">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Address:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><U>______________________________________</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone Number:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address:</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Signature:_________________________</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Address: _________________________</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Warrant Certificate Request Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT CERTIFICATE REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Computershare Investor Services, as Warrant
Agent for Aethlon Medical, Inc. (the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of Common Stock Purchase
Warrants (&ldquo;<U>Warrants</U>&rdquo;) in the form of Global Warrants issued by the Company hereby elects to receive a Warrant Certificate
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25px; text-align: justify; font-size: 10pt">1.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder of Warrants in form of Global Warrants: _____________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">2.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder in Warrant Certificate (if different from name of Holder of Warrants in form of Global Warrants): ________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">3.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Global Warrants: ___________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">4.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants for which Warrant Certificate shall be issued: __________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">5.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Global Warrants after issuance of Warrant Certificate, if any: ___________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">6.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Warrant Certificate shall be delivered to the following address:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed to have surrendered the
number of Warrants in the form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: ______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________________________________________________________</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Global Warrant Request Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GLOBAL WARRANT REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Computershare Investor Services, as Warrant
Agent for Aethlon Medical, Inc. (the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of Common Stock Purchase
Warrants (&ldquo;<U>Warrants</U>&rdquo;) in the form of Warrant Certificates issued by the Company hereby elects to receive a Global Warrant
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25px; text-align: justify; font-size: 10pt">1.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder of Warrants in form of Warrant Certificates: _____________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">2.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder in Global Warrant (if different from name of Holder of Warrants in form of Warrant Certificates): ________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">3.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Warrant Certificates: ___________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">4.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants for which Global Warrant shall be issued: __________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">5.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Warrant Certificates after issuance of Global Warrant, if any: ___________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">6.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Global Warrant shall be delivered to the following address:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Global Warrant Exchange and the issuance of the Global Warrant, the Holder is deemed to have surrendered
the number of Warrants in form of Warrant Certificates in the name of the Holder equal to the number of Warrants evidenced by the Global
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: ______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________________________________________________________</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="margin: 0"><B></B></P>


<P STYLE="margin: 0"><B></B></P>


<P STYLE="margin: 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>aethlon_ex0501.htm
<DESCRIPTION>OPINION OF BROWNSTEIN HYATT FARBER SCHRECK, LLP.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;<FONT STYLE="font-size: 8pt"><IMG SRC="image_003.jpg" ALT=""></FONT></TD>
  <TD STYLE="width: 40%"><P STYLE="color: #051C2C; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">Brownstein
                         Hyatt Farber Schreck, LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">702.382.2101 main</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">100 North City Parkway, Suite 1600<BR>
Las Vegas, Nevada 89106</FONT></P>
</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 5, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9635 Granite Ridge Drive, Suite 100<BR>
San Diego, California 92123</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the addressee set forth above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have acted as local Nevada counsel to Aethlon
Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), in connection with the filing by the Company of Amendment No.
1 to the Registration Statement on Form S-1 (File No. 333-278188) (as so amended, and including the preliminary prospectus contained therein,
the &ldquo;<U>Registration Statement</U>&rdquo;) with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) under
the Securities Act of 1933, as amended (the &ldquo;<U>Act</U>&rdquo;), relating to the (i) offering and sale by the Company of (i) up
to 4,651,162 shares (the &ldquo;<U>Common Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<U>Common
Stock</U>&rdquo;); (ii) pre-funded warrants (the &ldquo;<U>Pre-Funded Warrants</U>&rdquo;) to purchase in the aggregate up to 4,651,162
shares of Common Stock (the &ldquo;<U>Pre-Funded Warrant Shares</U>&rdquo;); (iii) common stock purchase warrants issued to the Purchasers
(the &ldquo;<U>Purchaser Common Warrants</U>&rdquo;) to purchase in the aggregate up to 4,651,162 shares of Common Stock (the &ldquo;<U>Purchaser
Common Warrant Shares</U>&rdquo;); and (iv) a common stock purchase warrant issued to the Placement Agent (the &ldquo;<U>Placement Agent
Warrant</U>&rdquo; and together with the Purchaser Common Warrants and the Pre-Funded Warrants, the &ldquo;<U>Warrants</U>&rdquo;) to
purchase up to 186,046 shares of Common Stock (the &ldquo;<U>Placement Agent Warrant Shares</U>&rdquo; and together with the Pre-Funded
Warrant Shares and Purchaser Common Warrant Shares, the &ldquo;<U>Warrant Shares</U>&rdquo;), all pursuant to one or more securities purchase
agreements (each, a &ldquo;<U>Purchase Agreement</U>&rdquo;) to be entered into by and between the Company and each of the purchasers
identified on the signature pages thereto (collectively, the &ldquo;<U>Purchasers</U>&rdquo;), and a placement agent agreement to be entered
into by and between Maxim Group LLC, as the exclusive placement agent thereunder (in such capacity, the &ldquo;<U>Placement Agent</U>&rdquo;),
and the Company. The Common Shares and the Warrant Shares are hereinafter collectively referred to as the &ldquo;<U>Shares</U>&rdquo;
and the Shares and the Warrants are hereinafter collectively referred to as the &ldquo;<U>Securities</U>&rdquo;. This opinion letter is
being delivered at your request pursuant to the requirements of Item 601(b)(5) of Regulation S-K under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In our capacity as such counsel, we are familiar
with the proceedings taken and proposed to be taken by the Company in connection with the authorization, issuance and sale of the Securities
as contemplated by the Transaction Documents (as defined below) and as described in the Registration Statement. For purposes of this opinion
letter, and except to the extent set forth in the opinions below, we have assumed that all such proceedings have been or will be timely
completed in the manner presently proposed in the Transaction Documents and the Registration Statement (including, without limitation,
with respect to the assumed combined public offering price of the Securities as stated in the Registration Statement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 5, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt">For purposes of issuing this opinion letter, we
have made such legal and factual examinations and inquiries, including an examination of originals or copies certified or otherwise identified
to our satisfaction as being true copies of (i) the Registration Statement, (ii) the forms of the Purchase Agreement and each of the Warrants
filed as exhibits to the Registration Statement (collectively, the &ldquo;<U>Transaction Documents</U>&rdquo;); (iii) the articles of
incorporation and bylaws of the Company; and (iv) such agreements, instruments, resolutions of the board of directors of the Company and
committees thereof and other corporate records, and such other documents as we have deemed necessary or appropriate for the purpose of
issuing this opinion letter, and we have obtained from officers and other representatives and agents of the Company and from public officials,
and have relied upon, such certificates, representations and assurances, and public filings, as we have deemed necessary or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt">Without limiting the generality of the foregoing,
in our examination, we have, with your permission, assumed without independent verification: (i) the statements of fact and all representations
and warranties set forth in the documents we have examined are, and when any Securities are issued will be, true and correct as to factual
matters; (ii) each natural person executing a document has, or at the time of such execution will have, sufficient legal capacity to do
so; (iii) all documents submitted to us as originals are authentic, the signatures on all documents that we have examined are genuine
and all documents submitted to us as certified, conformed, photostatic, facsimile or electronic copies conform to the original document;
(iv) all corporate records made available to us by the Company, and all public records we have reviewed, are accurate and complete; (v)
the obligations of each party set forth in the documents we have examined are, and when any Securities are issued will be, its valid and
binding obligations, enforceable against such party in accordance with their respective terms; (vi) each of the Transaction Documents
will be duly authorized, executed and delivered by each party thereto in substantially the form thereof filed as an exhibit to the Registration
Statement prior to the issuance by the Company of any of any of the Securities to be delivered thereunder; and (vii) after any issuance
of Shares, the total number of issued and outstanding shares of Common Stock, together with the total number of shares of Common Stock
then reserved for issuance or obligated to be issued by the Company pursuant to any agreement or arrangement or otherwise, will not exceed
the total number of shares of Common Stock then authorized under the Company&rsquo;s articles of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are qualified to practice law in the State of
Nevada. The opinions set forth herein are expressly limited to and based exclusively on the general corporate laws of the State of Nevada,
and we do not purport to be experts on, or to express any opinion with respect to the applicability or effect of, the laws of any other
jurisdiction. We express no opinion concerning, and we assume no responsibility as to laws or judicial decisions related to, or any orders,
consents or other authorizations or approvals as may be required by, any federal laws, rules or regulations, including, without limitation,
any federal securities laws, rules or regulations, or any state securities or &ldquo;blue sky&rdquo; laws, rules or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based upon the foregoing, and in reliance thereon,
and having regard to legal considerations and other information that we deem relevant, we are of the opinion that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Warrants have been duly authorized by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Common Shares have been duly authorized by the Company, and if, when and to the extent any Common Shares are issued and sold in accordance
with all applicable terms and conditions set forth in, and in the manner contemplated by, the relevant Transaction Documents, and as described
in the Registration Statement (including payment in full of any and all consideration required for such Common Shares), such Common Shares
will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Warrant Shares have been duly authorized by the Company, and if, when and to the extent any Warrant Shares are issued in accordance
with all applicable terms and conditions of, and in the manner contemplated by, the relevant Transaction Documents, and as described in
the Registration Statement (including due and proper exercise of the relevant Warrant(s) in accordance therewith and payment in full of
any and all consideration for such Warrant Shares as required thereunder), such Warrant Shares will be validly issued, fully paid and
nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The opinions expressed herein are based upon the
applicable laws of the State of Nevada and the facts in existence on the date of this opinion letter. In delivering this opinion letter
to you, we disclaim any obligation to update or supplement the opinions set forth herein or to apprise you of any changes in any laws
or facts after such time as the Registration Statement is declared effective. No opinion is offered or implied as to any matter, and no
inference may be drawn, beyond the strict scope of the specific issues expressly addressed by the opinions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We hereby consent to the filing of this opinion
letter as an exhibit to the Registration Statement and to the reference to our firm therein under the heading &ldquo;Legal Matters&rdquo;.
In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Act
or the rules and regulations of the Commission promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Brownstein Hyatt Farber Schreck, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>6
<FILENAME>aethlon_ex0502.htm
<DESCRIPTION>OPINION OF COOLEY LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 5.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 47px; width: 145px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Julie M. Robinson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">T: +1 858 550 6092</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">robinsonjm@cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 5, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1555 Sorrento Valley Road, Suite 203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego, CA 92121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to Aethlon Medical, Inc.,
a Nevada corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the sale by the Company of (i) up to 4,651,162 shares
of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;<B><I>Common Stock</I></B>&rdquo;), (ii) pre-funded warrants
(the &ldquo;<B><I>Pre-Funded Warrants</I></B>&rdquo;) to purchase up to 4,651,162 shares of Common Stock, (iii) warrants (the &ldquo;<B><I>Purchase
Warrants</I></B>&rdquo;) to purchase up to 4,651,162 shares of Common Stock, and (iv) warrants (the &ldquo;<B><I>Placement Agent Warrants</I></B>&rdquo;)
to purchase up to 186,046 shares of Common Stock, all pursuant to the Registration Statement on Form S-1 (File No. 333-278188) (the &ldquo;<B><I>Registration
Statement</I></B>&rdquo;) filed with the Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) under the Securities
Act of 1933, as amended (the &ldquo;<B><I>Securities Act&rdquo;</I></B>), the prospectus included in the Registration Statement (the &ldquo;<B><I>Base
Prospectus</I></B>&rdquo;) and the prospectus supplement relating to the Shares, the Warrants and the Warrant Shares filed with the Commission
pursuant to Rule 424(b) under the Securities Act (together with the Base Prospectus, the &ldquo;<B><I>Prospectus</I></B>&rdquo;). The
Pre-Funded Warrants, the Purchase Warrants, and the Placement Agent Warrants are collectively referred to herein as the &ldquo;<B><I>Warrants</I></B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this opinion, we have examined
and relied upon the Registration Statement and the Prospectus, the forms of the Warrants, and such other records, documents, opinions,
certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have assumed the genuineness of all signatures,
the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies,
the accuracy, completeness and authenticity of the certificates of public officials and the due authorization, execution and delivery
of all documents by all persons, including the Company, where due authorization, execution and delivery are prerequisites to the effectiveness
thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified
such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our opinion is expressed solely with respect to
the laws of the State of New York. Our opinion is based on these laws as in effect on the date hereof. We express no opinion to the extent
that any other laws are applicable to the subject matter hereof and no opinion and provide no assurance as to compliance with any federal
or state securities law, rule or regulation. We note that the Company is incorporated under the laws of the State of Nevada and that our
opinion is limited to the laws identified in the first sentence of this paragraph. We have assumed all matters determinable under the
laws of the State of Nevada, including the valid existence of the Company, the corporate power of the Company to execute, deliver and
perform its obligations under the Warrants and the due authorization of the Warrants by the Company. We have also assumed that the laws
of the State of Nevada would not impose any requirements or have any consequences relevant to our understanding of the matters addressed
in this opinion that would impact our conclusions with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With regard to our opinion concerning the Warrants
constituting binding obligations of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(i)</FONT>Our
opinion is subject to, and may be limited by, (a)&nbsp;applicable bankruptcy, reorganization, insolvency, moratorium, fraudulent conveyance,
debtor and creditor, and similar laws which relate to or affect creditors&rsquo; rights generally, and (b)&nbsp;general principles of
equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing) regardless of whether considered
in a proceeding in equity or at law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(ii)</FONT>Our
opinion is subject to the qualification that the availability of specific performance, an injunction or other equitable remedies is subject
to the discretion of the court before which the request is brought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(iii)</FONT>We
express no opinion as to any provision of the Warrants that: (a)&nbsp;provides for liquidated damages, buy-in damages, monetary penalties,
prepayment or make-whole payments or other economic remedies to the extent such provisions may constitute unlawful penalties, (b)&nbsp;relates
to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes
of limitations, trial by jury, or procedural rights, (c)&nbsp;restricts non-written modifications and waivers, (d)&nbsp;provides for the
payment of legal and other professional fees where such payment is contrary to law or public policy, (e)&nbsp;relates to exclusivity,
election or accumulation of rights or remedies, (f)&nbsp;authorizes or validates conclusive or discretionary determinations, or (g) provides
that provisions of the Warrants are severable to the extent an essential part of the agreed exchange is determined to be invalid and unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(iv)</FONT>We
express no opinion as to whether a state court outside of the State of New York or a federal court of the United States would give effect
to the choice of New York law provided for in the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the basis of the foregoing, and in reliance
thereon, we are of the opinion that the Warrants, when duly executed and delivered against payment therefor as provided in the Registration
Statement and the Prospectus, will constitute binding obligations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion is limited to the matters expressly
set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This
opinion speaks only as to law and facts in effect or existing as of the date hereof and we have no obligation or responsibility to update
or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may
hereafter occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the reference to our firm under
the heading &ldquo;Legal Matters&rdquo; in the Prospectus and to the filing of this opinion with the Commission as an exhibit to the Registration
Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section
7 of the Securities Act or the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Sincerely</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Cooley LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 3%">By: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">/s/ Julie Robinson</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Julie Robinson</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-left: 20pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>7
<FILENAME>aethlon_ex1020.htm
<DESCRIPTION>FORM OF SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.20</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin: 0; text-align: right"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of [&#9;], 2024 between Aethlon Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below)
as to the Shares, the Pre-Funded Warrants and the Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser,
severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE I.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1 <U>Definitions</U>. In
addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set
forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the second (2<FONT STYLE="font-size: 10pt"><SUP>nd</SUP></FONT>)
Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof,
unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers, consultants or directors of the
Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of
Directors or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to
the Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued hereunder, and/or other securities
exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided
that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the
exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations), and
(c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the
Company, provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its
subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide
to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Legend
Removal Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers
of the Company, in the form of <U>Exhibit C</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Permits</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $[ &#9;], subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement; provided that the purchase price per Pre-Funded
Warrant shall be the Per Share Purchase Price minus $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means Maxim Group LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately upon issuance and shall expire in accordance with
the terms thereof, in the form of <U>Exhibit B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Product</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission
and delivered by the Company to each Purchaser at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission File No. 333-[&#9;] which registers the sale of the Shares
and Pre-Funded Warrants, Warrants, Pre-Funded Warrant Shares and Warrant Shares to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Approvals</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Warrants and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in
United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>in the SEC Reports</U>, and shall, where applicable, also include any direct or
indirect subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, the Pink Open Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Pre-Funded Warrants, the Warrants, all exhibits and schedules thereto and hereto and any
other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Computershare Investor Services, the current transfer agent of the Company, with an address at P.O. Box 30170,
College Station, TX 77842, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means the Common Stock Purchase Warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants
shall have terms of exercise equal to five years following the Initial Exercise Date (as defined therein), in the form of <U>Exhibit A</U>
attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE II.<BR>
</B>PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1 <U>Closing</U>. On the
Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery
of this Agreement by the parties hereto, the Company agrees to sell, and each Purchaser, severally and not jointly, agrees to purchase,
(i) such number of Shares or (ii) a Pre-Funded Warrant to purchase such number of shares of Common Stock, and (iii) a Warrant to purchase
such number of shares of Common Stock, in each case, as set forth on such Purchaser&rsquo;s signature page hereto, for an aggregate total
purchase price equal to the Subscription Amount set forth on such Purchaser&rsquo;s signature page hereto. Each Purchaser&rsquo;s Subscription
Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo;
settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares, Pre-Funded Warrant, and
Warrant as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section
2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall
take place remotely by electronic transfer of the Closing documentation. Unless otherwise directed by the Placement Agent, settlement
of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company
shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s)
at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver
such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer
to the Company). Notwithstanding the foregoing, with respect to any Notice(s) of Exercise (as defined in the Pre-Funded Warrants) delivered
on or prior to 12:00 p.m. (New York City time) on the Closing Date, which may be delivered at any time after the time of execution of
this Agreement, the Company agrees to deliver the Pre-Funded Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time)
on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Pre-Funded Warrants) for purposes
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2 <U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) On or prior
to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) this Agreement
duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) a legal opinion
of Cooley LLP and a legal opinion of Brownstein Hyatt Farber Schreck, LLP (local Nevada corporate counsel to the Company), each such legal
opinion, substantially in form and substance reasonably satisfactory to the Placement Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) subject to the
last sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv) subject to the
last sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on
an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) a number of
Shares equal to the number of Shares set forth on such Purchaser&rsquo;s signature page hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v) a Pre-Funded Warrant
registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to such Purchaser&rsquo;s Subscription
Amount divided by the Per Share Purchase Price (rounded down to the nearest whole Share) (such number the &ldquo;<U>Specified Base Share
Number</U>&rdquo;), <I>minus</I> the number of Shares required to be delivered pursuant to Section 2.2(a)(iv), with an exercise price
equal to $0.001, subject to adjustment therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vi) a Warrant registered
in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to [ ]% of the Specified Base Share Number, with
an exercise price equal to the Per Share Purchase Price, subject to adjustment therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(vii) the duly executed
Lock-Up Agreements; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(viii) the Prospectus
and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) On or prior
to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) this Agreement
duly executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) such Purchaser&rsquo;s
Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3 <U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) The obligations
of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) the accuracy in
all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on the Closing Date
of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall
be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) as
of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) all obligations,
covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) the delivery
by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) The respective
obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(i) the accuracy in
all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all
respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific
date therein in which case they shall be accurate in all material respects or, to the extent representations or warranties are qualified
by materiality or Material Adverse Effect, in all respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) all obligations,
covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) the delivery
by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(iv) there shall have
been no Material Adverse Effect with respect to the Company since the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">(v) from the date
hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s principal
Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have
been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service,
or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude
in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE III.<BR>
</B>REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1 <U>Representations and
Warranties of the Company</U>. Except as explicitly described in the SEC Reports, which descriptions shall be deemed a part hereof and
shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the applicable SEC Report, the
Company hereby makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary which it owns, free and clear of any Liens, and all of the issued
and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries
or any of them in the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries,
taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors, a committee of the Board of Directors or the Company&rsquo;s stockholders in
connection herewith or therewith, in each case, other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>No Conflicts</U>.
The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the
issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not
(i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles of incorporation,
bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse
of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company
or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or
Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset
of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which
the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably
be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant
to Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, and (iii) application(s) to each applicable
Trading Market for the listing of the Shares, the Pre-Funded Warrant Shares and the Warrant Shares for trading thereon in the time and
manner required thereby (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Issuance
of the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company.
The Pre-Funded Warrant Shares, when issued in accordance with the terms of the Pre-Funded Warrants, will be validly issued, fully paid
and nonassessable, free and clear of all Liens imposed by the Company. The Warrant Shares, when issued in accordance with the terms of
the Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has
prepared and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on [ ],
2024, including the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The
Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration
Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose
have been instituted or, to the knowledge of the Company, are threatened by the Commission. At the time the Registration Statement and
any amendments thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments
thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement
thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) <U>Capitalization</U>.
The capitalization of the Company as of December 31, 2023 is as set forth in the SEC Reports. The Company has not issued any capital stock
since its most recently filed periodic report under the Exchange Act, other than pursuant to (i) the exercise of employee stock options
and granting of restricted stock units under the Company&rsquo;s stock option plans and (ii) the issuance of shares of Common Stock to
employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock
Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first
refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction
Documents. Except as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there are no outstanding
options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares
of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company
or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any
Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or
other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary
with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities
by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any
redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any
Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation
rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock
of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and
state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe
for or purchase securities. Subject to any stockholder approval that may be requested by the Nasdaq Stock Market LLC, no further approval
or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are
no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the
Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) <U>SEC Reports;
Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by
the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding
the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement,
being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension of
such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the
SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none
of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The Company has never been an issuer subject to Rule 144(i) under the Securities Act, or, if it has been an issuer subject to Rule 144(i),
it is not currently a &ldquo;shell company&rdquo; and at least one year has passed since it filed &ldquo;Form 10 Information&rdquo; with
the Commission. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting
requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the
periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and
except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development that has had or that could
reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise)
other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission,
(iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of
cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company
stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except
for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development
has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective
businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under
applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one Trading
Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) <U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;).
Neither the Company nor any Subsidiary, nor to the knowledge of the Company, any director or officer thereof, is or has been the subject
of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission
involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other
order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k) <U>Labor Relations</U>.
No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could
reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees is a member
of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company nor any of
its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement
or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any
of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the
failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l) <U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m) <U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as
all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits,
plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have received
all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and
(iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii),
the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n) <U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o) <U>Title to
Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each
case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal,
state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither
delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by
them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p) <U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have would reasonably be expected to result in a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;).
Other than as set forth in the SEC Reports, none of, and neither the Company nor any Subsidiary has received a notice (written or otherwise)
that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned,
within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest
audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual
Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material
Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement
by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q) <U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited
to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that it will not be able
to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r) <U>Transactions
With Affiliates and Employees</U>. None of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company,
none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other
than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending
of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder,
member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii)
reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under
any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s) <U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley
Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the
Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a
system of internal accounting controls with the goal of providing reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such
disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules
and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company
and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,
the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as
of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such
term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially
affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t) <U>Certain Fees</U>.
Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other
Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect
to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may
be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u) <U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company
shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration under the
Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v) <U>Registration
Rights</U>. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any
securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w) <U>Listing and
Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has
taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock
under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading
Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing
or maintenance requirements of such Trading Market. The Common Stock is currently eligible for electronic transfer through the Depository
Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company
(or such other established clearing corporation) in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x) <U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance of
the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y) <U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus Supplement.
The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities
of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries,
their respective businesses and the transactions contemplated hereby is true and correct and does not contain any untrue statement of
a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z) <U>No Integrated
Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither the Company,
nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with
prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the
securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa) <U>[RESERVED]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb) <U>Tax Status</U>.
Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect,
the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and
franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other
governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations
and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the
periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the
taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc) <U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts,
entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign
or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)
failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the
Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd) <U>Accountants</U>.
To the knowledge and belief of the Company, the Company&rsquo;s accounting firm (i) is a registered public accounting firm as required
by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&rsquo;s
Annual Report for the fiscal year ending March 31, 2024 (or such other fiscal year end then applicable to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee) <U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff) <U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections 3.2(f) and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked
by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company,
or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified term; (ii)
past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo;
transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of
the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which
any such Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv)
each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo;
transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various
times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Warrant
Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of
the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities are being conducted.
The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg) <U>Regulation
M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action
designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities,
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company,
other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh) <U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal Food,
Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Product</U>&rdquo;),
such Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all
applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance,
licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing,
quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material
Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened, action (including any lawsuit, arbitration,
or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries,
and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any
other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution
of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Product, (ii) withdraws its approval
of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials
relating to, any Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv)
enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of
permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations
by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The
properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable
laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license
or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any
concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) <U>Stock Option
Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance with the
terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock
on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&rsquo;s
stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice
to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public
announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj) <U>Cybersecurity</U>.
Except as would not reasonably be expected to result in a Material Adverse Event, (i)(x) there has been no security breach or other compromise
of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware,
software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or
on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) other than as disclosed in
the SEC Reports, the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would
reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries
are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems
and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as
would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and
maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster
recovery technology consistent with industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk) <U>Office of
Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll) <U>U.S. Real
Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning of
Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm) <U>Bank Holding
Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as
amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn) <U>Money Laundering</U>.
The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or
any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(oo) <U>Other Covered
Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that has been
or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(pp) <U>Notice of
Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become
a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2 <U>Representations and
Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date
hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(a) <U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(b) <U>Own Account</U>.
Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings
with any other persons to distribute or regarding the distribution of such Securities. Such Purchaser is acquiring the Securities hereunder
in the ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(c) <U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(d) <U>Access to Information</U>.
Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules
thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive
answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and
risks of investing in the Securities all such questions, if any, have been answered to its satisfaction; (ii) access to information about
the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it
to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire
without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Such
Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser
with any information or advice with respect to the Securities nor is such information or advice necessary or desired. Neither the Placement
Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent
and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided
to it. In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has
acted as a financial advisor or fiduciary to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21pt; text-align: justify; text-indent: 51pt">(e) <U>Certain Transactions
and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting
on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short
Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written
or oral) from the Company or any other Person representing the Company setting forth the material pricing terms of the transactions contemplated
hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed
investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the portfolio managers
have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&rsquo;s
assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that
made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement
or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners, legal and other advisors,
employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this
transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing
contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares
in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acknowledges and agrees that the representations
contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations
and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other
document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated
hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty,
or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.1 <U>Legends</U>. The Shares, Pre-Funded Warrants
and Warrants shall be issued free of legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2 <U>Furnishing of Information</U>.
Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to timely
file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company
after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3 <U>Integration</U>. The
Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section
2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would be integrated with the
offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder
approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent
transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4 <U>Securities Laws Disclosure;
Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated
hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within
the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that
it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its
Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement
Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such
press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether
written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or
agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of their Affiliates on the
other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each
other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser
shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect
to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company,
which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing
party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing,
the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission
or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities
law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required
by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted
under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5 <U>Shareholder Rights
Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is
an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6 <U>Non-Public Information</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be
disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide
any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material
non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information and agreed
in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries,
or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser
without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality
to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without
limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, not to trade on the basis of, such material, non-public information,
provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction
Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously
with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7 <U>Use of Proceeds</U>.
The Company shall use the net proceeds from the sale of the Securities hereunder in the manner set forth in the Prospectus, and shall
not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade payables and accrued
liabilities in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common Stock or
Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.8 <U>Indemnification of
Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers,
shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such
titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section
15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or
employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and
reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating
to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other
Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity (including a Purchaser Party&rsquo;s
status as an investor), or any of them or their respective Affiliates, by the Company or any stockholder of the Company who is not an
Affiliate of such Purchaser Party, arising out of or relating to any of the transactions contemplated by the Transaction Documents. For
the avoidance of doubt, the indemnification provided herein is intended to, and shall also cover, direct claims brought by the Company
against the Purchaser Parties; provided, however, that such indemnification shall not cover any loss, claim, damage or liability to the
extent it is finally judicially determined to be attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties,
covenants or agreements made by such Purchaser Party in any Transaction Document or any conduct by a Purchaser Party which is finally
judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any Purchaser
Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in
writing, and, except with respect to direct claims brought by the Company, the Company shall have the right to assume the defense thereof
with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of
such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there
is, in the reasonable opinion of counsel to the applicable Purchaser Party (which may be internal counsel), a material conflict on any
material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible
for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party
under this Agreement for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not
be unreasonably withheld or delayed. In addition, if any Purchaser Party takes actions to collect amounts due under any Transaction Documents
or to enforce the provisions of any Transaction Documents, then the Company shall pay the costs incurred by such Purchaser Party for such
collection, enforcement or action, including, but not limited to, attorneys&rsquo; fees and disbursements. The indemnification and other
payment obligations required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation,
defense, collection, enforcement or action, as and when bills are reasonably incurred and received; provided, that if any Purchaser Party
is finally judicially determined not to be entitled to indemnification or payment under this Section 4.8, such Purchaser Party shall promptly
reimburse the Company for any payments that are advanced under this sentence. The indemnity agreements contained herein shall be in addition
to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject
to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.9 <U>Reservation of Common
Stock</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times,
free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Shares pursuant
to this Agreement and Pre-Funded Warrant Shares pursuant to any exercise of the Pre-Funded Warrants. The Company shall reserve and keep
available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company
to issue the Warrant Shares pursuant to any exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.10 <U>Listing of Common
Stock</U>. For as long as any Warrants are outstanding and exercisable, the Company hereby agrees to use reasonable best efforts to maintain
the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing,
the Company shall apply to list or quote all of the Shares, the Pre-Funded Warrant Shares and the Warrant Shares on such Trading Market
and promptly secure the listing of all of the Shares, the Pre-Funded Warrant Shares and the Warrant Shares on such Trading Market. The
Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include in such
application all of the Shares, the Pre-Funded Warrant Shares and the Warrant Shares, and will take such other action as is necessary to
cause all of the Shares, the Pre-Funded Warrant Shares and the Warrant Shares to be listed or quoted on such other Trading Market as promptly
as possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading
Market and will comply in all material respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules
of the Trading Market. For so long as the Company maintains a listing or quotation of the Common Stock on a Trading Market, the Company
agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established
clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established
clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.11 <U>Subsequent Equity
Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) From the date
hereof until 90 days after the date hereof, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce
the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) From the date
hereof until one (1) year after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect
any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof)
involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company (i) issues
or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional
shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies
with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity
securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance
of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business
of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not
limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities at a future
determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement
is subsequently canceled; <U>provided</U>, <U>however</U>, that, after ninety (90) days following the Closing Date, the issuance of shares
of Common Stock in an &ldquo;at the market&rdquo; offering with H.C. Wainwright &amp; Co., LLC as sales agent shall not be deemed a Variable
Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which
remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Notwithstanding
the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an
Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.12 <U>Equal Treatment of
Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend
or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to
all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each
Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class
and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting
of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.13 <U>Certain Transactions
and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate
acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the
Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions
contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser,
severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement
are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain
the confidentiality of the existence and terms of this transaction (other than as disclosed to its legal and other representatives). Notwithstanding
the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees
that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities
of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial
press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any
securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by
this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall
have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any
of their respective officers, directors, employees, Affiliates or agent, including, without limitation, the Placement Agent, after the
issuance of the initial press release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a
multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the
portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such
Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio
manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.14 <U>Exercise Procedures</U>.
The form of Notice of Exercise included in the Pre-Funded Warrants and Warrants set forth the totality of the procedures required of the
Purchasers in order to exercise such Pre-Funded Warrants or Warrants, as applicable. No additional legal opinion, other information or
instructions shall be required of the Purchasers to exercise such Pre-Funded Warrants or Warrants. Without limiting the preceding sentences,
no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of
any Notice of Exercise form be required in order to exercise such Pre-Funded Warrants or Warrants. The Company shall honor exercises of
such Pre-Funded Warrants or Warrants and shall deliver the Pre-Funded Warrant Shares or Warrant Shares, as applicable, in accordance with
the terms, conditions and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.15 <U>Lock-Up Agreements</U>.
The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend the term of the
lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to a Lock-Up Agreement
breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms
of such Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE V.<BR>
</B>MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1 <U>Termination</U>. This
Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated
on or before the fifth (5<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2 <U>Fees and Expenses</U>.
Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any
fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser),
stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3 <U>Entire Agreement</U>.
The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the
entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4 <U>Notices</U>. Any and
all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed
given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment
at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day,
(b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email
address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City
time) on any Trading Day, (c) the second (2<FONT STYLE="font-size: 10pt"><SUP>nd</SUP></FONT>) Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5 <U>Amendments; Waivers</U>.
No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of
an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial Subscription
Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts
a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be
required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment
or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable
rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment
effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6 <U>Headings</U>. The headings
herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7 <U>Successors and Assigns</U>.
This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may
not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger).
Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities,
provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction
Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.8 <U>No Third-Party Beneficiaries</U>.
The Placement Agent shall be a third party beneficiary of the representations and warranties of the Company in Section 3.1 and the representations
and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit of the parties hereto and their respective
successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except
as otherwise set forth in Section 4.8 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9 <U>Governing Law</U>.
All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by
and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section
4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10 <U>Survival</U>. The
representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11 <U>Execution</U>. This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12 <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13 <U>Rescission and Withdrawal
Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction
Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not
timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion
from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to
its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission of an exercise of a Pre-Funded Warrant
or Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice
concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration
of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Pre-Funded Warrant or Warrant (including, issuance
of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14 <U>Replacement of Securities</U>.
If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to
be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor,
a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction.
The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including
customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15 <U>Remedies</U>. In addition
to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and
the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not
be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would
be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16 <U>Payment Set Aside</U>.
To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces
or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are
subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded,
repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any
bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation
or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17 <U>Independent Nature
of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and not
joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
Pryor Cashman LLP. Pryor Cashman LLP does not represent any of the Purchasers and only represents the Placement Agent. The Company has
elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it
was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this
Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers
collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.18 <U>Saturdays, Sundays,
Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19 <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.20 <B><U>WAIVER OF JURY
TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY
AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES
FOREVER TRIAL BY JURY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AETHLON MEDICAL, INC.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%; font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">E-Mail:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">With a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cooley LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10265 Science Center Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego, CA 92121<BR>
E-mail: robinsonjm@cooley.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Julie Robinson, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO AEMD SECURITIES PURCHASE
AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Principal Place of Business:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Address for Delivery of Warrants to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Funded Warrant Shares: ___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: __________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Form of Warrant</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Form of Pre-Funded Warrant</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Form of Lock-Up Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>aethlon_ex2301.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation by
reference in this Registration Statement and Prospectus on Amendment No. 1 to Form S-1 of our report dated June 28, 2023, relating
to the consolidated financial statements of Aethlon Medical Inc. which appears in the Company&rsquo;s Annual Report on Form 10-K for
the year ended March 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also consent to the reference to our firm under
the heading&nbsp;&ldquo;Experts&rdquo; in such Registration Statement and Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ Baker Tilly US, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">San Diego, California </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">April 5, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !, .H# 2(  A$! Q$!_\0
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M7MEG#0N<L!_LFO;=$UZQU_3TO+"8/&>&!ZH?0BO/JT)TWJ=L*L9&K12 Y_\
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;]I><?2NM48H%**XW.4G=G3&"CH@HHHH*/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  W *H# 2(  A$! Q$!_\0
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(HHHKM/BC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>aemd-20240405.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaGI2aPty552WYkxvmRxfWlazy0nE72NryevKpHmcecI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:AEMD="http://aethlonmedical.com/20240405" elementFormDefault="qualified" targetNamespace="http://aethlonmedical.com/20240405">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aethlonmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20240405_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20240405_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>aemd-20240405_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentCreationDate" xlink:label="dei_DocumentCreationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentCreationDate" xlink:to="dei_DocumentCreationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentCreationDate_lbl" xml:lang="en-US">Document Creation Date</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>aemd-20240405_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/Cover" xlink:href="aemd-20240405.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentCreationDate" xlink:label="loc_deiDocumentCreationDate" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentCreationDate" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ? ,X# 2(  A$! Q$!_\0
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@*OESQSX1UR\\<ZS<06.^*2Z=E;S4&1GW:II[E5=C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>17
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @
M6HN%6 =!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !:BX58II(O0.\    K @  $0
M@ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !:BX58F5R<(Q &
M  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+
M 0(4 Q0    ( %J+A5C8R;"_WP,  "X.   8              " @0X(  !X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !:BX58GZ ;\+$"
M  #B#   #0              @ $C#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( %J+A5B7BKL<P    !,"   +              "  ?\.  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( %J+A5BJQ"(6,P$  "("   /              "
M >@/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !:BX58)!Z;HJT   #X
M 0  &@              @ %($0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " !:BX5899!YDAD!  #/ P  $P              @ $M
L$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !W$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>18</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="aethlon_s1a1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aemd-20240405.xsd</File>
    <File>aemd-20240405_lab.xml</File>
    <File>aemd-20240405_pre.xml</File>
    <File doctype="S-1/A" isOnlyDei="true" isUsgaap="true" original="aethlon_s1a1.htm">aethlon_s1a1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="18">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>23
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aethlon_s1a1.htm": {
   "nsprefix": "AEMD",
   "nsuri": "http://aethlonmedical.com/20240405",
   "dts": {
    "schema": {
     "local": [
      "aemd-20240405.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "aemd-20240405_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aemd-20240405_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "aethlon_s1a1.htm"
     ]
    }
   },
   "keyStandard": 18,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 60,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 18
   },
   "report": {
    "R1": {
     "role": "http://aethlonmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-04-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aethlon_s1a1.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-04-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aethlon_s1a1.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>24
<FILENAME>0001683168-24-002158-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-24-002158-xbrl.zip
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MWH=0WW0M/\G->I/\M<(ID5O^"U!+ P04    " !:BX58Q;[&G6X'  !)60
M%0   &%E;60M,C R-# T,#5?<')E+GAM;,V<WU/C-A#'WSO3_\%-GT-(N&L+
M!^U #FXRQQV4<'=M7VX4>Y-HD*6,+)/DOZ]D)[G\L.3EQ0L/$)R5M-_/RK+7
MDGS^UR(5T3/HC"MYT>H>';<BD+%*N)Q<M+X,VY?#_F#0BC+#9,*$DG#1DJKU
MUY\__Q39G_-?VNWHAH-(SJ+W*FX/Y%B]BSZS%,ZB#R!!,Z/TN^@K$[D[HFZX
M !WU53H38,!^439\%KT]ZO58U&XCZOT*,E'ZR\-@4^_4F%EVUNG,Y_,CJ9[9
M7.FG["A6*:["H6$FSS:U'2^.5S]E\7/!Y=.9^S5B&426E\S.%AF_:+EV5\W.
M3XZ4GG1ZQ\?=SC^?;H?Q%%+6YM)QBZ&U+N5JJ2K7/3T][13?KDT/+!<C+=9M
MG'36[FQJMM_R@/V6)QD_RPKW;E7,3!'VVF8BKX7[K[TV:[M#[6ZO?=(]6F1)
M:PV_(*B5@ <81^ZOC=ZF509F:CM6"@F/F7!AZSB33E_9;FG]+0I/-8PO6@S2
MQ+;1>W/\YOBM:^'7'2.SG-GNF7'7NUI19Z?UF88,I"D$W]H#.T5@86RG@F1=
MD6O_9?X9;ER15<?I1FW7R_+4MF@_EI8K=]8."17O^"!<--2>X'7/+IAG$!]-
MU',G =YQ$-R'@D9!PO[SO6CH<I09S6*SKDFP$8BB_N_69L^DTX!7:Q*/ML9J
MIW8M]GW:#MVECB.E$]"6];HNIN.=@!UVTI5%9\:TK:@=3[G8Q'JL5>JCLR*A
M/(YN@[)--$/STK:?.!]N!)M4X]PS0?+L4@"M5$-%]#UDL>8SQZ4&[(XEDF^/
ME&^%MH8QK\^=!YAPYZ]SQ5UZP1T,CPN>(DCP)Y0C15 M400NI<R9>("9TC7@
M=RV1O-]0\J[21H3Y[YQI UHL,:0/C)&PWU+"]B@DXOVHF<RXXX,!?FB-)/X;
MZ8V'1R,1\N$4A'#I').H7EYEC\3^.R5VO\Y7 /[ZV5W?[:4%SWZK"!+_'Z\%
M_X%:H@C<@^8JL9=TC6!_8(RD?DI)W:.0E/>U3+"T-Z;H_(<>]IX\(M0W/(N9
M*#VZL<>R,.X*<RQRDIRS5B8I]G^!:33T+6,L<I(TM$9BP\#[N=8[S@1'%;\U
M%CE) EHGLF'FU])PLW3/_S_GZ>C'@]-=UH=66,8D2:=/% G;]9,&:=RT1HCO
MOB66,4FN&1)'PKEO]6@F!C*!Q4=8AD ?F&))D^2807DDJ.\U3YE>#GE</V@<
MVF)ADV2688$DM!_98I!857S,RXG!>NC>(ECV)&DE2BY)" 8R5GJFMAX7]U5N
MS\=E7R7!(;VF(#8<)/GF"Z23!.4R22RN;/7GEDOHAD)1:8Z>(Z(+0$#F*\'>
M>QGV'AX[21Y:*_.58#]Y&?83/':27+16)B7VOOUXIQ_5W#,#[37&(B?)16LD
M4@(OKC1W^EZK9UZNCZJC?E "BYXP10V+)>WPY44>T]O7EEC>A.EJM3A*SO<J
M,TS\QV=U=Y+5]ECFA(EK2&C3#QC+N+N'%KZE1'LF6+XDN6JEG*:1N@AK8/[N
MNVN!!4J2@%:):9CGK7)S'U,E@\]C#ZVP7$DR29^HI@=>MYPX\Y[Z6U^C5["1
M#*O[,AK&^$US8SWHJS3-Y>H9C6=6S&.*Q4N2_@7E-8QZJ 2/N>%R\LG>(6K.
M1#7G*CLL9))DSR^L8<+W&ERDP=YV%^NXW'X#?3<>^T;>D#V6.$FN5R^4EOP@
MRW+0+^5?40H;!9*T#RNZZ7$&XMP.>\MN;_3H=LQX1ID#*RQKDI3/)ZIAMI_5
MHV9NW]YPF8Z4\&\/J33$$B9)\ +2&H:\XT<UWCT3+%B2S*Y2#M&8<+V(ITQ.
MP+]ZH=H2"Y@DTPN)(QM[)ZBQ=_+"L9<DX_.)(F);K@VW9]3=2/ )\^\D"Q9
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M!;#ZMZWL6F+AD[Y/J$I<!>?SSH&$6WO O1.X_,;]<N^]M4?^!U!+ P04
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M 0$HBR1-_CE/&,TECJ:@ 9<&=09]?B#VLRBM%BS35 2;_8>=\.G3IRU"35Z
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MGU,GLK2D\;K20TC9X%=Q2]I*#J%="CI>Z(4>Q/>'O8W0Q551Z0,V28VTTU$
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M]2@UKBH7JJ;F_VBV6VXV-T<_33NJ4Y. G)KBY8@5.EFBGH[B]*0S>/XF&XQ
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MX+O5:-E:)-B>&MDV$!6RM<B,.@"&',!:<E);\>57$?&W%E!FVXP=SH]NP^Z
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MG:>;B/:/=AKO'4PB([OK)C!2S2K1='(OF((QM*?GF?C*2J[.(+]%HG01L,D
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MN)+S@@BD6(Y^5>,R*#/Z11+/XS(LXPQ&AV>5)AM\%'\_SM(HYE_/5*[B-)S
M6$&A2EQ].1L$80D/KX(2=AQ'@!73(]T.?CU"NL0O9I/JXALIU=LN7,,2WB6!
ME<!KZ>N&;RC?B8(X#2;+)*D.?@GO"VO%A7<[M8%'RS)(LQ)?,%>TV@'N!VQ-
M,<[CD:*#P=D7RWP\ \8:3/)L'FS*A(4#!X8!TZ6".X6L%S8,"/4JC$+8VWR1
MY;3(ZOH/L_D"=M5=-9XFKO*65SDHB#L%O;#09P]'DP5AA*0_!UJA\UD"Y>,N
M--&P,#AO"^$\88US6/E%F8T_[027\$VS78L\'BM\)DL5+Z#ZA8 F1")Q3A:>
MA*.$_5?_60)E"(D: CG#46'_BB!2DSCET[^ %\(-?-H;]7?NGTD\ '/:W?D1
M9X;ST>^^AT>S$\ G1[@Q?%_ILV[G,%S !4] B$3"!99X;Y"Z\0ID> >N<7?U
MGO(UE[.8A5>*#F&NPA0IR]Y\W'QD8\350CZ)90YSP\N>:4(83G.ED,BZG0J%
MUQ_QB1TY1W1KN44B"T@$Z&Q*ZY:+I/E9MZ-I-(=7@4T.RRQ?,2,HL_NE'SG'
M;X*"GAH*TK>-/O@=[ ?_'X>^Q1K"OKL5P+NZ'4>>[P3.;XC*#.,CI:P <;X
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MQP%QX7-D[BY*,WE*(]1ON\@(-<W@IP&-BI2R,$:,F;U7]+T%6%ID:0@6"8J
M+'C^8G<W6.S,=X(>*A#_S/)/P6%<LKCM!V(OV\M0*OO=)K'+YN5 KH@(=SN[
M*\NM[&;1/A'QZI!V72L>^&HL?ES@6F0*E^=T.UJL61O?V5[<(I!@FVU NW;1
M_ELM-9AF/?(+CK2Z04\B.P*"6V1XQ1WS$R3?51PA T'#8A&NR#Z5O6D5[CV1
M.C.X@"($D5F"T$'F49.O?>15VN&".T)[M&:YH!<?[/O7D@Z5O3(*#A\&"<=C
MM2B1Q59Y&QC^X?A3FETG*IKR'M(QBA,(OINKL+ T0)M0L$=&1@*]$+X2+F;H
M,TH2>]N-XMG$)RL,P.XS'] &#%3.B:=P!!@3]12V*&5:%KH7I284382985&2
M*2>$-0G'VB.T@Q&7K^B(_B)5_ULP-T:^N4%4+>;[I4?XCHH8-Q :_!Z)D-U7
M<.OG)*SK7_K?NSN[NWO! H[2.WK@8JC6Y.KQ! ^Z*L?A0OF\="VC&*!25H D
MA#=-5JA !F'$OD1X''\'-UU[OYP;3*1YP]+!C*^NO5]76G&)\.,BC,4*,S=8
M1,>9R@L68Z(0X(?*L^WL[GJ2V:B68 4IXW#5>P)VS#*GK<H5[B3=3E3FR*VX
MTO=T8(4O;#DML_6HM>:X"L9Q/E[."V$UN?@JX7"$BUP#5RDR=87\-$['R9($
MF?!%^!B5P[K3#;5D4H\J>JAWUE4[DK<D5ZB0X"3+%%^BVZFL?<$;UN8$;%H.
M;"J?], 59DT^RZJ]6+]%VE;\>MZ,[Y;1;-<@GB\]^_]Z_#AX':LD>@$VRE2]
MA"F088TQXA8\?JS#<T<G?V^*ZO^$,;E*&)\^DTBD_NP@ 04@V(.%%ED21S!_
M2>(5S;$%,L5T2N%/_+E8A&/]<U&N$O771ZUQS4K\LQ:@?%7F>HQJQ!/6WX@W
M*"/]#1GZV;,_PYG]:>^G73BS,FIZ H.CC4%K9W?UOKX,+E<+6. P#T?Q^&5P
M&LX5[_UIAAN^YW[IB?X6_J9M]F=_;HR+NDM^4N;X/]QS^!L.L^%<1\ ^/SUF
MI]D+D!E(#!N<-;SE0J_(H4L[_\*?T7T[?&LFLC_R71R3\G.HM73/_XSZ3\5U
M&B8%274CHMJ=J"1:23T=K2B (>X$$18UPT $A76Y6(VAV[&Q*4?8BQ6!RE:;
M,NVY F#X,B:39H0&/)L?40PV#XK/?_6&CP_Z0>\?_7_CY[UA'\U*$'0OOBF.
M;:$<+G2C"NWX>')T^>:OCY S?0&NP\-.-=P\9F_M@ [X(J(YZK@*(P 0U=#V
M6]CYZ@.-J*>__O"G7UZ"QFP]/"_(>8Y'_?>/P[.Z-V$5Q/.YBF)0GI(5JGUC
M91P=VAW3Z(<F8]8ZVT1O;/;#H<<%-FIFO?=H<UJ?!%ATQ5*<A-:I'/9UH)Z\
MUE&X8BL<!D3E,-1O@0Z/%5ZUWM.O,(V[-9ZNF2T4Z93PH-Q74(R729BC]YW7
M,<M@!GUI>WY8^'P)6_?3[FYO1'ZA<_HN+>'TW06:V/-E,B6[5.N@8)HJ-$B2
MH+"!S"2\+L@G0MOM+)9T>8P[L"WMGO;:<PPJQUCSPS4?J;]1C.-H?)@ (+_E
M5*R3:IQD; 4U[W_@;7]EBXA(7EKLD,4-?2TFMK<9"WO\A^5A![?@87681=VW
M@'R.["\)U=&]>8G4M3WF!SSF?]SRF%L5%6+VU]DRB5#+B0O@$LBV"$+6YA.A
MJ,<8@Q#DC4#_//-#1IK4GA8>9X:[!CJJ*&>HE=D'\M ZAAI<N3MW27K?HS+M
MP65&8'5.\PPN*MJ.6?X"U=I2/=H_L7@&X_/-^<Q9>M(I->PW!R-0P4;AV.[5
M;J +(VR>@;#I_:+! =V. QL:CB7< =H\B9@%[$L6M?BS1XH<6[QH<4"7L";Q
M-6>M(U5]>L:]*=$5@@;"U\-/2MQU!;DM3929!X=AW)"\\;[*S' ZB@*;XHS$
M&('5!D"Q& 0Y*"D%NPFU>E+L:*SVMZ3R/\P:C$\/M2O'D]?M$+\8:-<G*5!"
MFB2[(E62IU(9O^\DS@L32+(AE'$2+@O-^^AT$,>-VI"H9IZW,B; 1AHD,0E!
MA..@0<?T9C6T=V'^20DA1V$,>OY5EBSGR.W0-8$:&<@ M/T=+WYE*GPSNH2D
M&_8$O9(J)/S2L1OPUWWRR[MV!J_ #]RO?Y- 7B0D[%*6"W#I(,DR%!?3H#>B
MT'%-9R=@["\OGNT&X<X<[/7&F"*'79^V1QWA\J"BWK+I M5M6"[!>F0U[M*Z
M'=D"9$LP*FUT85! W@0A@Z12^^+P*V0+9W'Z*7@/9HC>SQZ%58IX'J,:G.73
M,!4X"SGVIRH=4S!QK,2HRT ;+V':93HN=3R/9R&61(OJ,Z',LZ(D=P*PC%$<
M-7G.:RLO,K-F-D?&?6*\"$8AL8E1T&+ ;'82QCE>2GP1QIR3N&WVRY,MY=XA
MBJQ&:J'HBN)5R4.0!P@$3X 'LM289L!A81Y@]G+M7/0EAR> ^2&CY6 I,D+A
MEF<6EDGKFH>_9CG21XPSPU*4O;^.Q*"#<V ; S'D%(/=U6=8L<!(^"H8-PY'
M*OQU;B,$^Q4$!B$^U@.N-.^IQ(8&+6&=< E:<5@*^LH&FJ[B!GW#6*N$]JB)
MW.UY;=>P7<-V#=LU;-?P':QADZCSTVW4^0&BSD^W4>?O_"[N[3S=<!&/=^G1
M1_L1!9[?*; [TGA<>!&VKYO]]*4KO).-VONYFDF^]K!BR2L4/&Q6=QU^0 ^Q
MMW$-"/(Q.EJ:O'@6EFXA78S;HRP;SC72]N2E3KP93I4Q"@PH#QX:YPHAAA)1
M11?DT@*(^3&=J:-SJR/%*%[S^2A,R&NIOTW>2WRC(T6>0$P8O,QASZSCL)SE
MV7(ZH_'D*1S^(WP3$X%"3(L*#N$K612#*5VLBE+-@Y[U<!U]'!YZ>4W6%4*;
MJ!TV(3M?Q_%"O._D).+QT%8#DS<FT[\W[%?354 *1"TG8"*"L#B&0B*J(5?3
MN"@%HDDHWCE[-/%CFS4!8X2)JCAI#1;=!UZBE^*@WY@HDZL B&P::]RQ#.M_
M'\\"S'WM4<O0I9&F(*:RR6-ZW,MG-\!(<L'2XAT7$&TLO/,8_IFL^)C)M*6,
MFA+V993$8]ADS%(3-P]\,@V-+X>"S'O/GZ/CQ=U%_3D&I8OEG#R-8MHZX$A_
MP] 11,E[I4[(A3?7>4HV6X]C)%Q'8$QFMCX.FP$F[V8(FGT\^CEYJMM)P[GR
MKT;U2@S,=K5'C;(:5B9P2A!XV^+'?OCN M%&48XVOTUD\X]<7JHY'<^$SS54
M@3SO88Z.W%+G,I;7&8$5O PG&^?6>VO8B9,*V3)SCQU:)HEE77H"US$P*8IV
M)[WE(!'F<4$N%_)QH0,FS"-@Y"5L)-'N&<<PZBMOR.'\&@OO=GK&![VV-("?
M+N%A;EDZN.3;LK+*POS<#PS-W"[YPP83_=R/A@PZRM>!'69W,@DK*<R@;)(*
M[##"HQ'N#4>E3&R)CY(3L5KB5&[6DGM?'.]8/0%P$,2Y? =9<>8C12S)-D[I
M"V";,V02QT*;PHINZ])<GYI\P<%?AW"7ANRWPT16ZW[5\KC;.<NS:1Z"3'L]
MO+A$? W^U$<7=8*I^&$15-+]<"V%Z[H5ARV]/^K,.\%0:A6PYW'@4%_[[:B'
MB>@5"OV%PGZ!0X(8ML-D;4FZ#%LNJ/%S5IDKW-IY2!J!%WNII:K5XPX%SJ<S
M$=/&\VV_+[?*E9-\!YT/O'&NW-[3+\\56Y,1QVF$]Y(29Q*]VS+B* 1P]REQ
M]37Y/+/;N9>4N#:NZ&;$T8[<F!+WL$;)@QI&S_9V?D1;._9-(^+%.)]6Z)H,
MHY,*(L;)2ZXG@#.0V:5U>IRPS:QX_V<I:D[HI0P39L<FAE=A.)[Z*&/IZU?E
M//X]&M@[YEE>P#7MBP<*"38=&UU&BF+XJB9FX>N;C1\O4VL)5BXOAHI$.E>*
M:6@FX\[.6^K%084-%I2LA6LCIY36^!TXR%>GJ)UG/VY,5#\OOGZYQB\S^86R
MSU4!M%A0#:US.D.'B)W: F&<$/^U-KYOIQ.QB#%?(9P;S%$;[(OZO;AOXK5K
M.-. #67/9G13_XD8&;L/;Z>!M Z@[ _+U_3I7]'AGV;!ZSP<<[JFL>;A"EZ,
M\WC!A #/3,PSNM 8(E?P$5L$![63^G-&- J"R]2J:T_ '!8FZU^/YZ(8:H8H
MHQD=B]K/WC#\1_BE0P=M;!>M8T(\8/HFV/+L;%D@)IN1BTZ*(A5H8/U+@[NY
M>H99>W/-"'Y2/S/'LA@(3#)V<16H"]HW@?RD/AP#A3Z7DA-#6[,EZ^T:OJ$U
M;!((>[8-A#U (.S9-A#V![N++.T/04I,<=S+\+,J.))P+. Y4?HP(4"JFU2-
M:RW)L::=<=&/:<B*OJ<1NR3S T9OLJ98AI\#4T L!NL!5XF:AV#X*N(4QXR=
M)=4-5G@9*<LE>@&^F8\*]," %<SBP&99U<KK5#07,;!;_.FB6?!O<_H;"_H:
MQTB<,X#2\WJ_Q$/1IC\>P  _F&776->!?D;3"LO'5 H[@([2$%CA@)I=;BC+
M*?VJ&[47J(#XKE&S-G8EFV1.0,-B_,9CVD1':1E2K1S2BUY3T3\J$VBK_OG5
M!OT(@':Q:'4,=TYB.IR69*L4D\&) ^I,!>,N 25Q.8?_)F#XQF*4Y"J>C\#<
M@*TI#6EZ%&D),9"!FX*;I/_!W]7P).%030( 8;IABQ]'E.N8C5512(9C2Q4M
M2JJ <2?BX"K7!"$9G9SRD:H"N6U<X :/$Q7F9(N[]887*L>P%LZO <T&IMQO
M63,IOGF6QN,;W 1;=7/_BDWHPR23,^YV#K+L4U&/CY-YBA!WSK=$"Z- ![%$
M%T;X+<X1X6)O9#2L).XIO T,+;S_A7'E).UU; 94 ]>8V*7)UI*B3+_#L[L5
M.D41+,3'"G0[YDZ^M0'F-JP#'N8&!858PH3U:I5U7X4>@CWG7IDO=[Q&UXF1
MJM=LUWK929SX0D[X:7R%E"H+UW:HD;'\D+,0MQ1TMD'U5"_RUBNSJ2)69<+N
M%73&$!AU@GGRQ< 47&/FQE6;,/V,ZT62!, \-S1_FT?5A9>:@2!VJH #GC*#
M&W$:EF4>CS@P<<;Y;VZ<LP^W2N=.I@I%#,';LVLR\C$QK# .T /S1/#^&NYP
M,8L7#EEYF>Q4YK6_@S+31@=,&I,$>P*J-)R.E:1ZV B6=LE4TCNJ:VR4N,B(
MG)W!CQHVP;A;L="4<B+<Y YOF7_#Y-+FP"F'I"4[A7<LULF 7%09R_OSLF#C
M<5G5>G<MR^+Q6U)@$4A0A6Z8RE=8W2QUBF8U7U!T/]^P\99.*]L/OVC:?0,M
ML$O+41L"V5PX,;2ELSA4V6"U_%#IK]9>,J<&0N:[>WNFJ-C Z/H6=3-PQO V
M]Q@TBJLP02G5]QL1.-\..,G2K-XR'!@V3+)IMC2*D/,M3$8)W>+UM]OG;N?&
MC<:2WY3<&=8JX"LG'<]>Q$GMPGJY*PA$L(ND)1(?<.K,C,-DC$FAHK&W9-/N
M/>M%IM VK!%T>3"ZAN/2:,V<9,KP"I-EZE7 *)UP8USR5?)J5M;*Y\TD:N3
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M /3(7[;HD>_HCMU6Y7MHA1,TS@/I+D/Z!ZM6(@C9LJKV1D%@I<UGU0'C-GC
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M#MX?_1,5FR=O+M^]W?__4$L#!!0    ( %J+A5BJ6)B.SD@  &G> 0 2
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MAY>+/7<'/KA<G;H%0D:,SS9_^^V/%&_\C?XFAH'.2?G7GM%738NO3U_3SO6
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M;E5MC*M0M\MA:UDX3L6==_]=@"U3LWH=A!Z&/)QZ,HLM81(M[2/31[+JBP@
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M-V_#]A$X1FRHZ;#1%7Z<%SL;MG2S?M:+^J'3$]>X=EX/.<IR7CCNC>;PIS)
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M<^?;X;D)OD!73P9#;7IYCA3VL8KI_>P>["$TU/]LX8V"97RBL O \*"D4<E
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ME8V_^4E/=*%W_'UN<7Y^\5QN5!_POTQ %DTX'LY?8Q9"?VOQWP\_J$6_8,
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M6S$?]!A/V;/%Z-\5,1LJV-&@36)C-C"N"3?^<(X?QG +7,FW!US)%\"5?'O
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M!V!O#&CJ%(S@(B0N(HN_P=CQR,3'H_/'KYZJ(R:!P>.K/8,2F[OK$?E\1AM
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MF4D!,RAX;WESN('!)O7M6[9=R_T=(BS-S=H\4AJ%>((8;+!#97M'?;2BFA:
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M]<%SO_9SG,G]GW [E@AYPF+VQ%3+^#2&2=+[X+P_IJYL,$ON1MJ7,<_>%G%
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M/8-5:^!&5.2"MSYW9<ZHF#+;HW,E!*&%%GV&X[IHHT.LS"Y'BDC-P:TU7CP
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MOWUDC09C9 Y+08EB[,3E\$]\O[-=1LZ^=%9C.W&_I?N%[YAA'<Z/?]"L'%'
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MY/?$ML>:";8^7N5#G"\EZ8;!XME2PQ @;:G.02B/QD08A)S +D=*/4QG0MQ
M)^ TH 45CKT(/&L1^^0_;6D0 I^1.2]Q2JCI(F&<,<FJ87VU%0JP@8W64C'O
M2J9*RT-(,.PBE4(#HU>P8EX%9B@'>S<MUF'3[D &R6+<G0)H%J^&PVU&B@O2
M66PSI',HVUA(ZN6 6I%;Q"#/14<BK#F?M[3[9BU!,\=TJ@H^% 7-&D5ZMB*
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MEOF8!S(G""&@/X7/+GD$<QS;[OA2:&W4)[ <%1B906B'B7K<7I X5=;$ECD
M<2+D[A# &,IC< OE1RK 6;RK*,/+21?9YFN:,2*ZM@$R\I#\ WO3?*L#TK_A
MYM&9%@#3Z$0>4HUYB2'T,F6,,AJMY*!>SB*4''8L7,I>J*L-5I+:(U-T297'
M!KKLR*.<L+U@I'XRP*<EEM \%^8:8\*F#2*Z7CU@&_+DG.O4*AQ!DX7Z$?ND
M,T(6FCXN8BCY$'(RR5<W.-M/>!Y^HE"K_E1$IJBQ!7$:Q(36 Y  X\FT^< 5
MFXCZFL0)!Q=(_QB /U,,(^"Y1?3GX)V,OL01WU*X;]#</P=D;DX=Z+^HR0$P
M1<CF:M%IUX4?]G(PVNR%]: .)UX!Q*B1Q[,%-44G)+#8:2"(1!B2XGFAV=;5
M+Y2UFB[4<L(#6-\49AT0:]$WK0 )J+B\@V(T,1T%OEQX#()=ZJ&7UJI7N537
M[T1YRP)[(\;-(%F$FNEQ%EX!<5$?G VA@%Q!*56H67$IIE[995V:4(&N/M)O
M==R)+=OO+\68K,PF<HTG<!06\#"&C2 D5ZE!&C!<?'*)!KPZA6:&*YTPKB4/
MIH@C\<8I11((WCI=2OD*NPZT96S?!IZ;@S5"-I#S^65K T=),>L,*SF#MT*#
MO>(W@LX4=#9/U1$# 19U)N&\(",3<3"E]/\(#J@N=G-8B8#2YRN<"?09>XYD
MWDB,(265!!@[($'DG2IS'.-*$;)DPN 8#B;T3[B3,0U_2PKU,GXP,PN4V*8=
M8%8%;P1ZL/QONG\JQ>'+]"&H[J"&S\&.:ET$*_IC4&'TMJ)QL0 (XV,5VG'<
M3:E44A9_>'$!L>/<0J$1.;Z0I=HK4P>&YJYF&)R@K)!D& '*59DZI!"."/ME
MMU7BVR]_OX*XPV+LL.NR'#D&>+$SG>MB+TY"0R-\=(K]H$O/LZR>)^(%M6YE
MA^O8\ZTP"[LU9N$Q, N[-6;A!>^\/28GZUMGM(.S=9U/^]A&,T'7/UB'>*$^
M5?D<EXL\GI+'-4WGZK)6!_PT2JB23361+ME&*A0":WTT4M4$V^,\$K47B/^+
MEA"%Z<\I= \6!%6VDW82J[M,*?@A^8I7!0.$QPA<6RP*I2S9:.'I"DNK=6P#
MU*.@>B!1[V3EO) .#U(?X%"DJ B D)+RL 0WYVH \TDX0JW$PO4O-[N:00J[
M3W(]@91&9V0)6T$))49N&" ;Q]CR*,Z440RV/V12K/*$F60EC.N+&)77%$*B
M(+FQ )0UI-:<6J891/"5J9G$^7(+\G+IB%C+3>B\J"]E&POK'*3=HUUY&8UE
M$T)P47(L7&<&NRVR='A, 02$30@5Z]2 (C&<)ING?)'-GPVU<A*(9#4=9B<H
MXX&P7M5>H,@[45 &JN2P,JJL*UCUAS:D&<)7[/JG293#HN*AH0>%KAI$>\;J
M:H+EC?&L9!Y:Y\ 2-XU#<4!+6?*X3("A?K(]NP*-\BK4B<E0LY@KPHR1%$WH
MM%=EI=&D7T'SI;T.*W)+J0P"=E!XV6.A)*@5"Z\H(N/,Q_IM':R,.&4IVD&4
M>S[D' 1Z)^B,7(?H[37,/-9&R3:3?\XUE%P[<44*^\KX A[!5N2" E&D;6C"
M&!:,/=<XC0;?/)C+*(^'(1\S2B :OEL'8Y%YMOB>I(7U+1AF"+FSI-"<^&@A
M+#C)P@64[/- U!T8@<<;0ZP-U?I@HAMRBC!G-6HY7*094\W"*#+7&4???(*N
M90.3?R&%[0P 3[N$I>"&EX.B<$2]1B(:4L3U20@HP1/O=B0BYV'R1[:8Y2,^
M)0FRHQH7Q [^=D0Q V@U9;E!<B708H$9'K%-@2&@W%E^3L69\>(+Z7-<*LY;
MDR0)OB[&7-(\D@$!D LK[/$5JRL9 ((:WF,WFKXB:R.+[DLXEF,6"!Z #UA"
M$86UIA9!.IG(%T1A<;Q^9Q#6_;35KV<1_DWY591 <VI .;;B]:Q+!UX%!F2M
MHJX"E*)00F/6=G6 $T(])/ @]]'F!NH[6.H.Y>+#0N%@@[^[@K)^!HE=4EW5
M.!;!I#GW6D;8#/,K3>!_\QAN>-+5N!NVYZ^'-#8HIY2DO&4YB5WD/C.GO@$X
MYD(04P'OL1!%10-JSEA) #=^B6<HSRE&,N5R0A+B &28KK[5#_$'!HXG9&\M
MT6G1^5_ 3RPN9WR:5 C\9,ZKND&KA^1F2]PPSAO+2C#3"I6%E1:?*TE2K3(9
MF^T$ $!U[^62_1/DDG6-WH(B7RIGLYCXH!95I8]P#RWRVV4K$*]<T-A,(D!N
M@=4Z<2\F0XB/)S>\:-)1"A.;+UL#H7 5&O23C@:SX!10DKF3"(1V>&)K. V]
M!IBD]"HQC/D$-F8>,<D^P+6A#D9;;NHF_#7*8<$%#J8U;>+Q99S$RM>D)&BY
M!K6BVK> %I9A899Q!-B$A+:5,&=8N&TMS/ %(;*;&Z?94DU3,YQ_46>-U^F<
M;GNE7^F,CYDG.S_E>CSDRNL/LNB56\KAEE:J[VYN8)*%5C'[8^BBV=P/#I:"
MA&6@OVJ70XY69T(+.BCL>IQ'9(K$.6!F7;X@^+<R.VA@8[6K4\T!6'QX21\;
MLCL++*.!E5P;2? ;6_G,E:,I@C+CQ$;E5-YB\6H6R-"^I2!I-ETVK,=?31UI
MG@[R-Z@A2U#QXI>Q%V7F710G9>WL&JQP&H M WK'JD6U"N ?FQO'$$G'WT7Y
M:!ML%\"APGQ-@<($SK[9#"XSM0S&EG6@;EF+C"_4N$@RDV=QYF#9*8EEKV$)
M9K@(6SY\0^^ %;F)E\BD8;DCX3K%JUY.5.K$0.#0?=+\*LC^A%5*=!#;/:S?
M@L#BGZ95RV.5N%6$<*Q8$HH+O:$W[4KB.$<^W4/LOX!C 2"Q&7!M+)*8>#_@
M(ZP_4GE<HF'7T%%;!BLE8(!.O6PQC;A.Q_! BILF)*H,Y LOS^.+!?-/4#$^
MF;_I%#TL2^UZG(63W&"/F<>$ER67K^BXTK?4.+$1H4DW-#VA$R#DFQ5M(PSH
ML:_.&7S,^E*J6>LT5"7!8\WM53Z1M8UF9\K'L%[PSQ.\7Y [A.I<TNP*BJ3F
ME%V?3=4]C^R8\.,XQF#X>-[@OZOK_9SY;&TXML!)'#/37'QFX/C*T/VTR-F$
M-FRMY6CVMG=_\(!Z_NSC)[_]:]#W>H?>SV?]SVK/]MM^AV/-7<_O?O;\YK#=
MZZH^S]K#AM?K>Z?]7C,(6NWND7Q$?;4]:+7Q@]Y!OW=V=#ST#C[CWT[]_E#]
MZ\AO=P=#_$UO>*QZQ-^K!SH.\)_M8. %?O/8^Z7;^Z2:[JBQ^-V6ZF$8=*%=
MO].!C_?P&T?]P!\&JKW@-_BS=QKT3]K#8=#"7D]/.^VF?] )O([_J>&IW@+X
M]<&@USD;!M#,6;?9Z[;:IMUVOQ_\VH,OP:A;JMW3?C 8J)]P@@:;&X<]]0DU
M;IP@Z ;F:_L>2<P?;^WH7''[XZN!ANB>8KC]$$GXMGYZT[YW\O:V?LJ7UI?3
MRW5XA[<UWN$Q\ YO:[S#<]M=3_2F51?DI_:PJZX2[Q/<0[W#AHVC)DXL9311
M9 .<=$,F(. )\35=1B,(,"ZF2P.ZIN"::T6'B_Q+FB'O*=5:I,@7'&J#"<TA
MU.2$:F.L&@8C%B0%GX)--,1;',0Z!J=^4YD%>"3!SZ=^JR4_?_/HG!-KY<GV
M'6Z7GX9]Z:!X?M$._$YVU;#E-7LPT.X_O]O5O_VKDT<J)L'PN*-LJQ-E=C7]
MCK)7NDW+]KBKCFR"7GP[Q$ZEG*1];S&;*2<XA&DI2+@@52\,Y*<WPY:9#/T9
M^Y<KZ7^M#ZO_]/_:U%?U_,##X0_R2MNKNAD/EOO5H[G^YM;+]]W[[ZL?M=#Y
MSNT^]NY#U2#O:B)*#>.E>XM7]#COK=3P$%(0#S3>-WCL?;R#D_?.K[ZU;-"W
MZ+N)LG__*0\W>'T2QM,G/<1/R"_"Y!$I\,C$5(? 85LK84K%%5M/^G&::3J-
MEI!(NL-&=W[8?;_G#4:4V6FB+>VU,F76W6$G@S#Q6G%TD3:\IN_]?7=G=X=T
MT@*L2E:.3'H>)_,T^?WR7R-\RNU1>GF7>ROG"L-][^?%-([4EZC#AA?,_W=W
M-NC3/V>J?:=_]X,3O]UM48SNU#\*W)"8UPD.A]Y!Q^_^<L\C&;2/NO[PK!_0
M* XA$GC6;Q[[ S6VPUZGT_LT^,\]C^%!IKSN9$T[N55([ET=DGN,D-R[.B3W
M[/;3PUR0YA)R;Z@!)(O\X$0Y7T'SK-_&%)-\>'/#/^H'P8FZ2)_UG?6G@H^$
MVD&BG,V-QX\\>CKPN+GQ9"*/]](S13T<#9A][[]_\G_W/=0'C-IC9R;3J.;'
M-\MGP,MGZ<P;#&I_<^/19^EAETW5M'SS"GH94X(!N3N;DQ<R*0%2B4F\:M7D
M//RDW(/W?4H,R\"0#-!;>%A!X3WI6-$#1"?ADC87S%,>^[U.1LMBU&.*DKDS
M-=ZK>$)L?L@].!=:6:3:>Q:!1UO?SR-YOWWO;\]J'Y-\8<6!_90'7<&#4_$<
M3_D)KAGV,QA]H%R;[@*(X%?>]"_C0J][6>=>;A60W*L#DH\1D-RK Y+/9T<]
M;!KAX&/PVW'[H#WT_'O$AS_L,YU]/ 0"3&-*0XW 4S81Z@;K!NL&ZP;K!NL&
MZP;K!K\!!G\;K^M][74]AM?UOO:ZGL@^N='W.7B!OD\Y[EN[076#=8-U@W6#
M=8-U@W6#=8-U@W6#=8/W'X'XL8Y /$8$XL<Z O%$]LF-$8CF"XQ =-+1'Z_/
M9J8BXTX#$"^]6*CNI.ZD[J3NI.ZD[J3NI.ZD[J3NI.ZD[J3NI.ZD[J3NI.ZD
M[N26X?</__!Z6'<[W_<ZH&Y31^,?(1K_X4&C\<^;I.F>&S3-Z0]5SG2!/9K'
M\N:@U_H,K;PY'IYT/OX?4$L#!!0    ( %J+A5@A*9%9&0(  -\'   2
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MW?YP92%]]T W+[9[V)\ 4$L#!!0    ( %J+A5@3>4'9(;P  +//!  0
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ME^//IA,M>Z<EFLNZV4"Y,SH__.7GW_[Q^O+;V<!6VVQ3[_M1R]KLH;7YFSG
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M"A8/_I8IH\6M;TX43[_U]6^GS8=%^-$7H8FS5$/><'U2FRV/U%Q3Y5V]]CW
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M;'4DB#QDB-S-J;E5SHO5*$BP[S\R[!,XW.'KMR?^AS?^T8?WYR?OS\^^N1S
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M"8PV=PWR0]" %#5M=\.(>@Q^W0$[:J&N"Y5+;4N$1D>P8@J+'8HQ6?L6M<?
M:+;M2"[Q$EQA@>^F#\$CEPGZ"94&0A6^&?I)QAD*Q,MRC3N$H:+(MI#%2GFA
M^%:YM[Z!;K?5VVUO0*RS -8HQ85A&6E[;";5;5YI=W MW\'%.\!UIE7 (E9
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MXP':E*84S\BE]=J@Y5S(1/""%JP3YV"C@LR>3?N>\!U=IL+L'5\TO%_N#HI
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MQ7^P%RI-)A)770T6,%=DZ4M+ADT<A[\!*S65#CR@;C*/9U.V\+<$A<"VP#(
M')>"EW. !6*RZYG_F!-PJ#X-Q<QQ_)+<H]<8>%MH+LZ9 G3PZL?M2>"Y,28:
M?U,PBF'H_ZZRO!J;&]J!Z<-.;<W'D@*L, F=\%H)28&_*V$U-2(S2P4-5XJ
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M0AQ*CEY6-*,<\#%@;(''A*G2T-13U/PALVD^*/.CPW(4CS!_A4F1^[1N!GR
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M]5[O,%7J^U$P- "N0/R']42;>9!5"AD1F7^\81(6YD&J=T-I0FR=("2T2&&
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M-%K(-2R[-K[ZY E(U#D%+HH:F>2UPU? BXQ[+#"% .5\$_"Z#H)H_JGAV)M
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M4/!O+4+!N]4(A3L]"S;>H$.2FAM5X/WDSQ/T;NO/50,6O&\,6/!O.V#!^Z:
M!?^V Q:\NPA8N L2[ H_\#LC#WP3>>"[00;>>@49K'L6^'HWMX)K^?F#:_D/
M<"WO/+B6U^%XS E3\IT()7]QA))7XY^W%(SD+PE&\N?%'7G?&'?DWR#NJ&T7
MNN40H[O8YGGQ +S=5!AH22B =_>A /[R4 #O)J$ _C*OOW\SK[_?</![-W;P
M^W?@X+<;LZJ#W_]F![^_W)?OU?#93AO"<CCO4;^6LM$\:3PE*FP[J!<=U$88
M,CE9>.#FA@:"YNMF9#2SF19%)01V&;&>$7:C762U5?0>DS/1677<4U;LGPC%
M=3B:H]KB6H/2'<=(W 6G612/T%GGK1&*X-U)U(&[Z*Z%:VZ @7<+ 0;^:@$&
M_BW'$JR[4/[0W$-S#\T]-+>VS:U@-=A_L!K\ 5:#W0>KP>^@YS4[9ZM Y/4W
M78B\CV\/"1OO^/3L_-/IZ\^(E?> A#=WMSX*%KS@OZGT HA*8N,DZB@@92@2
MY>B-&N05QE=N/0\\#JP!%9P$8WXY\M^%U_'8_SG/JHG_]NU1(*7:FG%W 9<Z
M8$F_0GE7JO"T O2HSE@2#[$H UK=:Y @7EU1-G;YB3.S9A0<E6Y&%US&(!N(
MQ;T!&C_H8(4_"(M8\&B[EL-J Z@Z [/ (9@B<..8'4 ::J<]$P,O@&^T(*H,
M+DEWE*(N9U^KR3V(T\B#6=44H7+.\ 6/I-&X1%C(V,B(AJ/BPA,RT#GK/$
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M2L@A%L*QD4KHX%+!-PL)UE=@=YL.OI$=/FH&5!Y2$US*CR7#!;A81H!->#:
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MC!P+0\(<." UP5.EM["6"M#?>(/$QPX00*(W-TU Y>95=-VT\0 8SW*#)*)
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MQHW1^74YA*\/OSCVNW<?JFWY[QEK:DK>OC=Y:DJ^9VY&*:UV5E&T#4H^CJ+
MFPMZK77II?1JU>2Z#4^R0*YK)=9VJ]G^X8=[DN*#ZC7:K5;'<)WC/T6.=-D<
M7KLT<_HL"G=/9.<\.="(,JB],.$BX@_4SX9*/=Y'(VY[!;]^XPUB=@^W9$5"
MD0^T6[O_6!O*&1[T>WP;7JFS,L+HJ_7DU9X6_6JN\ RY0N?QN0)&^UO=SH'B
M"NW6G[O$&;K,&9C4A74=>V1G4Y=B9 H#+[W!1N;E[ ,_\:N+1<IO8O<+EB:/
MB(/H0#87 AQN.Q_HWH,/R!!]S09J-G!'-M#=)C902%$L#C54/($Z49RK]H!
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M=C.G9@DOYYI\_ !IBWZ*T?6Q'X,ZF*$D(+U2"\W02Y*F_2&.0._S1HX]B6Y
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MJ0T$,A!%G SU@Q3%-%B18Q27:3Z0)M2S# TDVL#-TDD4 ]<8D5M83;!P[&,
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MY>+,D,'W$ICA=-KH5(L4%>AY\ 3O^(P>'1(RBE36&NS?R#O-#\.C.K/C]HG
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M,B1>QT8)YT13JQ!G_PU02P$"% ,4    " !:BX58AM;4,BP#  #U"P  $0
M            @ $     865M9"TR,#(T,#0P-2YX<V102P$"% ,4    " !:
MBX587Q1-41P+  "2B   %0              @ %; P  865M9"TR,#(T,#0P
M-5]L86(N>&UL4$L! A0#%     @ 6HN%6,6^QIUN!P  25D  !4
M     ( !J@X  &%E;60M,C R-# T,#5?<')E+GAM;%!+ 0(4 Q0    ( %J+
MA5C%IYMW34H  /_I 0 2              "  4L6  !A971H;&]N7V5X,#0P
M-BYH=&U02P$"% ,4    " !:BX58F31B,Q \   &7 $ $@
M@ '(8   865T:&QO;E]E># T,#<N:'1M4$L! A0#%     @ 6HN%6*I8F([.
M2   :=X! !(              ( !")T  &%E=&AL;VY?97@P-# X+FAT;5!+
M 0(4 Q0    ( %J+A5@6/D\.AP\  )E    2              "  0;F  !A
M971H;&]N7V5X,#4P,2YH=&U02P$"% ,4    " !:BX58K[^7^N0-  !?.@
M$@              @ &]]0  865T:&QO;E]E># U,#(N:'1M4$L! A0#%
M  @ 6HN%6/DC%[PBC   4SL# !(              ( !T0,! &%E=&AL;VY?
M97@Q,#(P+FAT;5!+ 0(4 Q0    ( %J+A5@A*9%9&0(  -\'   2
M      "  2.0 0!A971H;&]N7V5X,C,P,2YH=&U02P$"% ,4    " !:BX58
M$WE!V2&\  "SSP0 $               @ %LD@$ 865T:&QO;E]S,6$Q+FAT
M;5!+ 0(4 Q0    ( %J+A5@=CJ=0;0\  !H0   -              "  ;M.
E @!I;6%G95\P,#$N:G!G4$L%!@     ,  P _@(  %-> @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>aethlon_s1a1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aemd-20240405.xsd" xlink:type="simple"/>
    <context id="AsOf2024-04-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2024-04-05</startDate>
            <endDate>2024-04-05</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-04-05" id="Fact000003">true</dei:AmendmentFlag>
    <dei:AmendmentDescription contextRef="AsOf2024-04-05" id="Fact000004">Updating S-1</dei:AmendmentDescription>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-04-05" id="Fact000005">0000882291</dei:EntityCentralIndexKey>
    <dei:DocumentCreationDate contextRef="AsOf2024-04-05" id="Fact000010">2024-04-05</dei:DocumentCreationDate>
    <dei:DocumentType contextRef="AsOf2024-04-05" id="Fact000011">S-1/A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="AsOf2024-04-05" id="Fact000012">Aethlon Medical, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-04-05" id="Fact000013">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-04-05" id="Fact000014">13-3632859</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-04-05" id="Fact000015">11555 Sorrento Valley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2024-04-05" id="Fact000016">Suite 203</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-04-05" id="Fact000017">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-04-05" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-04-05" id="Fact000019">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-04-05" id="Fact000020">(619)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-04-05" id="Fact000021">941-0360</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="AsOf2024-04-05" id="Fact000022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="AsOf2024-04-05" id="Fact000023">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-04-05" id="Fact000024">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140184826312784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Updating S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aethlon Medical,
Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3632859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11555 Sorrento Valley Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">941-0360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentCreationDate', window );">Document Creation Date</a></td>
<td class="text">Apr.  05,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentCreationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentCreationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
